Inference about treatment effects using bounds, sensitivity analysis and instrumental variables by Richardson, Amy
INFERENCE ABOUT TREATMENT EFFECTS USING BOUNDS,
SENSITIVITY ANALYSIS AND INSTRUMENTAL VARIABLES
Amy Richardson
A dissertation submitted to the faculty at the University of North Carolina at Chapel
Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in
the Department of Biostatistics.
Chapel Hill
2014
Approved by:
Michael G. Hudgens
M. Alan Brookhart
Stephen R. Cole
Jason P. Fine
Haibo Zhou
c© 2014
Amy Richardson
ALL RIGHTS RESERVED
ii
ABSTRACT
AMY RICHARDSON: Inference about Treatment Effects Using Bounds, Sensitivity
Analysis and Instrumental Variables
(Under the direction of Michael G. Hudgens)
This dissertation considers conducting inference about the effect of a treatment (or expo-
sure) on an outcome of interest. In the ideal setting where treatment is assigned randomly,
under certain assumptions the treatment effect is identifiable from the observable data and
inference is straightforward. However, in many other settings observable data may only par-
tially identify treatment effects or may identify treatment effects only for some subset of the
population. In this case three approaches are often employed: (i) bounds are derived for
the treatment effect under minimal assumptions, (ii) additional untestable assumptions are
invoked that render the treatment effect identifiable and then sensitivity analysis is conducted
to assess how inference changes as the untestable assumptions are varied, or (iii) instrumental
variables are used to identify treatment effects for a subset of the population of interest. In
this dissertation, first we review approaches (i) and (ii) in various settings, including assess-
ing principal strata effects, direct and indirect effects, and effects of time-varying exposures.
Methods for drawing formal inference about partially identified parameters are also discussed.
Second, we derive the large sample properties of instrumental variable-based treatment effect
estimators and test statistics when the outcome is subject to right censoring and competing
risks. These results are applied to a real data example about the use of antiretroviral therapy
to reduce mother to child transmission of HIV. Third, we derive identification results for
direct, indirect and total effects of treatment in presence of interference (i.e., settings where
the treatment of one individual may be affected by the treatment of other individuals). These
results are applied to a real data example about rotavirus vaccination. All derived asymptotic
results are supported by simulation studies.
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW
1.1 Introduction
The goal of many health and epidemiological studies is to gain insight into the mechanisms
that cause disease or other health outcomes and then use that insight to prevent disease and/or
better health outcomes. These mechanisms may consist of one or more causal pathways
in which different exposure states or risk factors lead to various effects (Rothman, 1976).
Epidemiological studies often seek to investigate not only whether or not various sets of
exposures or risk factors are on any of the causal pathways to a health outcome of interest Y
but also the size and nature of the effects of these exposures on this causal pathway.
In hopes of gaining some information on causal effects of exposure states suspected of
being on some causal pathway, data is collected and analyzed on some set of subjects or units
in either a controlled experiment or under observational settings. However, as often noted by
statistical scientists, effects estimated using conventional statistical methods can only mea-
sure association and do not have a causal interpretation. To estimate causal effects using
more conventional methods, assumptions that are strong and often empirically untestable
are needed. If these assumptions are dubious, resulting causal effect estimates are subject to
biases and inferences may be misleading. In order to untangle differences between associa-
tional effects and causal effects precise mathematical notation and language is essential. The
counterfactual or potential outcomes framework dating back to Neyman (1923) and formal-
ized by Rubin (1974) allows for precise definitions of a myriad of causal effects and allows for
distinction between associational and causal effects (Holland, 1986).
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1.1.1 The Potential Outcomes Model
Using the potential outcomes approach from Rubin (1974), let z denote the various levels
of the exposure or factor for which causal comparisons are being drawn, and Z the observed
value of the exposure z which is observed prior to the outcome of interest Y . The potential
outcome Y (z) is defined as the value of the outcome under exposure status z; for example,
z might be a medical intervention or treatment with z = 1 denoting treatment received and
z = 0 denoting control or treatment not received. The potential outcome Y (1) would then
be the outcome had treatment z = 1 been received and Y (0) the outcome had control been
received.
Causal effects at the unit level can be defined as some function of the potential outcomes
Y (z) that compare different levels of the exposure z. In order to define sensible causal effects
each level of the exposure in the effect must be able to be observed in the units under study.
For example, an individual causal treatment effect might be defined as the difference between
an individual’s outcome under treatment compared to control, Y (1) − Y (0), which is not
well defined if it is not possible for an individual or unit to experience both z = 0 and
z = 1 (Holland, 1986). Often the target of inference in health and epidemiological studies is
some population level parameter or population level causal effect such as the mean difference
between the potential outcomes under treatment and control, E[Y (1] − Y (0)] or average
treatment effect (ATE). Here E[Y (1)] is the mean potential outcome of the target population
if everyone were treated (Z = 1), and E[Y (0)] the mean potential outcome if no one were
treated (Z = 0).
In order to make inferences about these population causal effects, assumptions regarding
the relationships between the observed outcome Y , the observed exposure Z, and the poten-
tial outcomes Y (z) must be made. One of the first assumptions regularly made when studying
causal effects under the potential outcomes framework is that each level z of the exposure
Z maps to one fixed potential outcome Y (z). A second basic assumption connects the ob-
served outcome Y to the potential outcomes Y (z); specifically it is assumed that Y (Z) = Y ,
which means that the observed outcome is equal to the potential outcome under the observed
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exposure Z. This assumption has been referred to as a consistency assumption in the litera-
ture (Cole and Frangakis, 2009) and will be termed causal consistency here to avoid confusion
with concepts of statistical consistency. With this assumption, one potential outcome for each
individual is observed and known, but the potential outcomes Y (z′) for Z 6= z′ are termed
counterfactual and are unobserved. A third basic assumption frequently made in studying
causal effects is that the exposure of one unit under study does effect the outcomes of other
individuals or units, this is referred to as an assumption of no interference between units.
Collectively these three assumptions are often referred to as the stable unit treatment value
assumption or SUTVA (Rubin, 1980).
The assumptions contained in SUTVA will be reasonable in many situations, but unfor-
tunately are not strong enough to allow for estimation of most population level causal effects
such as the average treatment effect, E[Y (1) − Y (0)]. Under SUTVA, the observation of Y
and Z for some population of units allows us to estimate E[Y (z)|Z = z], thus allowing for
estimation of the associational effect
E[Y (1)|Z = 1]− E[Y (0)|Z = 0], (1.1)
but estimation of the ATE, a causal effect, is not possible without further assumptions. Under
experimental settings the observed exposure or treatment Z might be under the control of the
experimenter and random assignment of Z to the units under study would give plausibility
to the assumption that
Y (z)q Z for z = 0, 1 (1.2)
(here q denotes statistical independence). Under (1.2) E[Y (z)|Z = z] = E[Y (Z)] and thus the
average treatment effect may be consistently estimated using the estimated associational effect
(1.1). In absence of random assignment of Z, (1.2) may be dubious and an estimator based
on (1.1) is subject to bias. Specifically, the associational effect (1.1) between the exposure Z
and the outcome Y may have resulted from some unknown or unmeasured factor(s) X that
is associated with both the exposure and the outcome. The factors in X are said to confound
the effect of Z on Y . Epidemiologists often seek to measure different variables in X, if this
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can be accomplished then (1.2) might be replaced by
Y (z)q Z|X for z = 0, 1, (1.3)
which will be plausible if all factors that confound the causal effect of Z on Y are measured
in X. Under (1.3) the ATE may be consistently estimated using by weighting by the inverse
probability of exposure z
E[Y (1)|Z = 1;X]
Pr[Z = 1|X] −
E[Y (0)|Z = 0;X]
Pr[Z = 0|X] (1.4)
which is a function of associational parameters that may be consistently estimated from the
data. Estimators based on (1.4) are referred to as inverse probability of treatment weighted
estimators.
1.1.2 Instrumental Variables
Measuring all factors X such that (1.3) holds is one of the biggest challenges of causal
inference in epidemiological research, particularly because it is not possible to provide evidence
that (1.3) holds using empirical statistical tests. If there are factors U not measured in X
that confound the effect of Z on Y (z) then the resulting inverse probability estimators will
be biased. A method to potentially avoid this problem of unmeasured confounding entails
the use of instrumental variables. A variable R is considered an instrumental variable if it
meets the following three criteria: i) R has a causal effect on the exposure of interest Z, ii) R
affects the outcome Y only through its effect on Z and iii) R does not share common causes
with Y (Herna´n and Robins, 2006).
Specifically, under a set of assumptions that may be more reasonable than (1.2) or (1.3),
the instrumental variable allows for estimation of a causal effect known as a local average
treatment effect or a principle treatment effect. To illustrate, let Z(r) be the potential values
of the exposure Z for different levels of the instrument r, without loss of generality assume that
the exposure Z, the outcome Y and the instrument R are all binary. Define SP0 as the vector
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of the two potential values of Z(r), SP0 = (Z(0), Z(1)), stratification of the potential outcomes
Y (z) by SP0 is commonly referred to as principal stratification (Frangakis and Rubin, 2002).
A local average treatment effect or principle effect is the average treatment effect in one of the
strata defined by SP0 , where causal effects in the strata defined by SP0 = (0, 1) are commonly
of interest. Imbens and Angrist (1994) showed the local average treatment effect (LATE)
defined as E[Y (1) − Y (0)|SP0 = (0, 1)] is identifiable under four assumptions: independent
treatment instrument
R q {Y (z), Z(r)} for z.r = 0, 1, (1.5)
monotonicity with respect to Z
Pr[Z(1) ≥ Z(0)] = 1, (1.6)
exclusion restriction
Y (0) = Y (1) if Z(0) = Z(1), (1.7)
and if there is a nonzero causal effect of R on Z, namely
E[Z(1)− Z(0)] 6= 0. (1.8)
The monotonicity assumption (2.21) states there are no individuals such that Z(0) = 1 and
Z(1) = 0, meaning that the principal strata SP0 = (1, 0) is empty. Assumption (1.7) states
that Z has no effect on Y in individuals who are always exposed SP0 = (1, 1) or are never
exposed SP0 = (0, 0). Assumption (1.8) indicates that the instrument R has a causal effect
on the exposure Z. Under these four assumptions the LATE can be expressed as
E[Y |R = 1]− E[Y |R = 0]
E[Z|R = 1]− E[Z|R = 0] . (1.9)
Under these four assumptions, (1.9) is simply the ratio of the average associational effect
of R on Y and the average associational effect of R on Z; (1.9) is referred to as the in-
strumental variable estimand (Angrist et al., 1996; Herna´n and Robins, 2006). To see that
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E[Y (1)−Y (0)|SP0 = (0, 1)] equals (1.9), first note under the assumptions that the numerator
of (1.9) equals E[Y (1) − Y (0)] = E[{Y (1) − Y (0)}{Z(1) − Z(0)}] = E[Y (1) − Y (0)|Z(1) >
Z(0)] Pr[Z(1) > Z(0)]. Similarly, the denominator of (1.9) equals Pr[Z(1) = 1] − Pr[Z(0) =
1] = Pr[Z(0) = 0, Z(1) = 1] = Pr[Z(1) > Z(0)], which is non-zero under (1.8).
Obtaining a valid instrument such that (1.5–1.8) hold can prove to be a difficult task. An
example of a variable R that might satisfy (i)-(iii) such that (1.5–1.8) hold is the calendar
time for the FDA approval of a novel treatment for a disease, where here Z would be the
novel treatment. Let R = 1 denote that diagnosis of the disease was after the calendar
time for the approval of the new treatment, and R = 0 indicate diagnosis was before this
calendar time; let Z = 1 denote that the novel treatment was selected and Z = 0 denote that
treatment was not selected. The principal strata vector would indicate a subject’s treatment
selection before and after the calendar time FDA approval for the novel treatment, for instance
SP0 = (1, 1) would be represent individuals that would take the treatment regardless of the
FDA calendar time approval. In this situation Y might represent survival to a given time
point after having been diagnosed with the disease, thus the local average treatment defined
as E[Y (1) − Y (0)|SP0 = (0, 1)] would represent the difference in the proportion surviving
amongst those who took the novel treatment versus those whom did not in the principal
stratum wherein individuals would take treatment only after the FDA calendar time approval.
The assumption in (1.5) states that there are no factors that confound the relationship
between the outcome Y and the instrument R; randomization of the instrument R can insure
that this assumption is met making instruments that can be randomized attractive. In a
randomized clinical trial with noncompliance a commonly used instrumental variable is treat-
ment assignment (here the exposure would be the actual treatment taken). Another example
might be randomized treatment assignment in an encouragement randomized trial where sub-
jects are randomly assigned to be enrolled in programs that encourage (or discourage) the
exposure Z, while others are randomized to control, or no encouragement program. In some
situations natural randomization processes, such as Mendelian randomization, might provide
a valid instrumental variable. For instance, a study investigating a causal effect between low
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serum cholesterol and cancer might use a genetic determinant of serum cholesterol as the
instrumental variable (Martens et al., 2006).
1.1.3 Interference
When studying causal effects of a treatment or exposure, sometimes the treatment or
exposure received by one individual may affect the outcomes of other individuals under study.
In the causal inference literature this is referred to as interference and is most frequently
encountered in settings in which outcomes are largely dependent on social happenings. Some
well known examples of settings where this might occur include the study of infectious diseases
and vaccination, educational interventions and effects of housing voucher programmes. Until
recently most of the causal inference literature has operated under the assumption that there
is no interference between units (Cox, 1958, this assumption is included in SUTVA). In the
aforementioned settings this assumption is not only undoubtedly violated, but the pattern of
interference between units is often a target of inference useful in determining important social
and public health policies.
Though most of the causal inference literature operates under the assumption of no in-
terference, Rubin (1980) noted that the potential outcomes framework could be extended
to accommodate interference between units. Specifically, assume that there are N > 1
groups or communities for which data are observed, with each group having ni individuals
for i = 1, . . . , N . Let Zi = (Zi1, . . . , Zini) denote the treatment selections or exposures of
those ni individuals for each group i. Assume that Zij is a dichotomous, taking values 0
for no exposure or treatment not selected, and 1 for exposure or treatment selected. Let
Zi,−j = (Zi1, . . . Zij−1, Zij+1, . . . , Zini) denote the ni− 1 subvector of treatment selections for
group i with entry j deleted. Define Z(ni) as the set of possible treatment selections for a
group of size ni. Zi,−j takes on values in the set Z(ni−1). There are 2ni different realizations
of the vector Zi, and 2
ni−1 realizations of Zi,−j . For each subject in each group we extend
the potential outcomes such that there is a separate potential outcome for each permutation
of the treatment allocation vector Zi. Denote the potential outcome for the jth person in the
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ith group for treatment allocation vector Zi by Yij(Zi). Denote the potential outcomes for
all members of group i as Yi(Zi). This allows for interference between members of the same
group, but does not allow for interference between members of different groups. This is an
assumption, and is referred to as partial interference in the literature. In Manski (2013) this
assumption is a specific case of a more general class of assumptions which he calls constant
treatment response assumptions (CTR). This assumption is reasonable if interaction between
members of different groups is minimal or nonexistent.
Halloran and Struchiner (1995) took Rubin’s suggestion and defined several new causal ef-
fects unique to studying interference: direct, indirect, total and overall effects. The individual
direct, indirect, total and overall effects are defined as
DEij(zi,−j) =Yij(zi,−j , zij = 0)− Yij(zi,−j , zij = 1),
IEij(zi,−j , z′i,−j) =Yij(zi,−j , zij = 0)− Yij(z′i,−j , zij = 0),
TEij(zi,−j , z′i,−j) =Yij(zi,−j , zij = 0)− Yij(z′i,−j , zij = 1), and
OEij(zi, z
′
i) =Yij(zi)− Yij(z′i).
The direct effect compares potential outcomes that keep the treatment of other members
of the same group constant and comparing the effect of treatment in the individual. The
indirect effect compares two different treatment allocation vectors given to other members of
the group while holding the treatment given to the individual constant at zij = 0. The total
effect compares both the different treatment allocation vectors and the effect of treatment
in the individual. The overall effect compares any two treatment allocation vectors for the
whole group and may correspond to a direct effect, indirect effect or a total effect, or another
effect.
Often it is still of interest to compare 2 specific treatment allocation strategies or laws,
denoted pii(Zi, α0) and pii(Zi, α1), say for example comparing causal effects when vaccinating
1/3 of the population versus vaccinating 2/3 thirds of the population. The parameters α0 and
α1 index the two treatment allocation law of which comparisons of causal effects are desired.
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For the purposes here, a Bernoulli type parametrization of pii(Zi, α0) will be assumed:
pii(Zi, α0) =
ni∏
j=1
α
Zij
0 (1− α0)1−Zij (1.10)
Sobel (2006) introduced the idea of defining causal estimands that average over all possible
treatment assignment vectors according to some treatment allocation law in a paper assessing
the comparative effectiveness of different housing voucher programmes. Specifically, let
Y ij(z, α0) =
∑
s∈Z(ni−1)
Yij(zi,−j = s, zij = z)Prα0(Zi,−j = s|Zij = z)
and
Y ij(α0) =
∑
s∈Z(ni)
Yij(zi = s)pii(Zi,j = s;α0);
then the individual average direct, indirect, total and overall effects are defined as
DEij(α0) =Y ij(0;α0)− Y ij(1;α0),
IEij(α0, α1) =Y ij(0;α0)− Y ij(0;α1),
TEij(α0, α1) =Y ij(0;α0)− Y ij(1;α1),
OEij(α0, α1) =Y ij(α0)− Y ij(α1).
Now the direct effect compares the effect of treatment in individual ij while holding the
treatment allocation strategy constant, the indirect effect compares the effect of the treatment
allocation strategy constant while holding the treatment to the individual constant at zij = 0.
The total effect compares both the treatment allocation strategies and treatment given to
individual ij. Group average direct, indirect, total and overall effects can be defined by
taking the mean for group i of DEij(α0), IEij(α0, α1), TEij(α0, α1) and OEij(α0, α1) (i.e.
DEi(α0) =
ni∑
j=1
DEij(α0) and so forth). Population average direct, indirect, total and overall
effects can be defined by taking the mean of the group average direct, indirect, total and
overall effects (i.e. DE(α0) =
N∑
i=1
DEi(α0) and so forth).
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The so called gold standard for achieving accurate estimates of causal estimands compar-
ing these two allocation strategies is 2-stage randomization, where both individual treatment
assignment is randomized as well as treatment allocation strategy to various groups or com-
munities. The majority of the inferential methods developed for the population average
direct, indirect, total and overall effects rely on the assumption that there are two levels of
randomization. Rosenbaum (2007) developed nonparametric inferential methods for assessing
treatment effects in presence of interference under 2 stage randomized treatment assignment.
Hudgens and Halloran (2008) formalized the definitions of direct, indirect, total and overall
effects averaged over all possible treatment assignment vectors and developed unbiased es-
timators and corresponding variance upper bounds for these causal treatment effects under
2 stage randomization and an additional assumption referred to as stratified interference.
Stratified interference assumes
Yij(zi,−j , zij) = Yij(z′i,−j , zij) for
∑
j
zij =
∑
j
z′ij .
which means that potential outcomes will remain constant when the same number of other
members of the group are treated and treatment to the individual remains constant. This
reduces the number of potential outcomes for each individual from 2ni to ni. Tchetgen Tch-
etgen and Vanderweele (2012) improved upon the variance bounds developed by Hudgens
and Halloran (2008) for these effects under 2 stage randomization by relaxing the stratified
interference assumption.
Hong and Raudenbush (2006) consider interference effects in the context of educational
performance. In this setting randomization is not present at either the individual level or the
group level. The independent treatment assignment assumption that 2 stage randomization
makes plausible
{Y (zi)}zi∈Z(ni) qZi
for i = 1, . . . , N is replaced by
{Y (zi)}zi∈Z(ni) qZi|Xi
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for some set of covariates Xi. Tchetgen Tchetgen and Vanderweele (2012) derived the follow-
ing inverse probability of treatment weighted estimators for Y i(z, α0)] (the group average) to
be used for inference of the population average direct, indirect, and total effects
Ŷ IPWi (z, α0) =
∑ni
j=1 pii(Zi,−j ;α0)Yij(Zi)I[Zij = z]
nifZ|X,i(Zi|Xi)
for a the Bernoulli type parametrization of pi(Zi, α0) given above and where fZ|X,i(zi|Xi) =
Pr[Zi = zi] is the estimated probability of treatment allocation vector Xi given covariates
Xi. Tchetgen Tchetgen and Vanderweele (2012) suggest using a logistic-normal mixed effects
model to estimate fZ|X,i(Zi|Xi).
Though the advancements made account for interference and allow for definition of causal
effects specific to interference, many of the results obtained are limited by the need for 2
stage randomized designs requiring randomization at the individual level within each group,
as well as randomization of groups to different treatment allocation strategies. Such designs
are difficult, all but infeasible to implement in practice, thus there is a strong need for adap-
tations to be used for observational data or for randomized designs not necessarily having
achieving randomization at both the group and the individual level. Both Hong and Rau-
denbush (2006) and Tchetgen Tchetgen and Vanderweele (2012) have obtained results for
observational data under the assumption that conditional on measured covariates, treatment
assignment is independent of the potential outcomes. Hong and Raudenbush (2006) devel-
oped results for estimators of interference effects within strata defined by different levels of
Xi and Tchetgen Tchetgen and Vanderweele (2012) derived inverse probability of treatment
weighted estimators of interference effects. Both the results of Hong and Raudenbush (2006)
and Tchetgen Tchetgen and Vanderweele (2012) enjoy the same results obtained under 2 stage
randomization in terms of inference, but are limited by the fact that they rely on a strong
conditional independent treatment assignment assumption and require measurement of all
covariates required for conditional independence of the treatment and potential outcomes.
Manski (2013) develops bounds for interference effects under assumptions that are weaker
and maybe more plausible than the conditionally independent treatment allocation of Hong
11
and Raudenbush (2006) and Tchetgen Tchetgen and Vanderweele (2012), but such bounds are
only for effects pertaining to group level or population level means in presence of interference
and are not for causal estimands averaged according to some treatment allocation law.
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CHAPTER 2: NONPARAMETRIC BOUNDS AND SENSITIVITY
ANALYSIS OF TREATMENT EFFECTS
2.1 Introduction
In many areas of science, interest often lies in assessing the causal effect of a treatment
(or exposure) on some particular outcome of interest. For example, researchers may be
interested in estimating the difference between the average outcomes when all individuals are
treated (exposed) versus when all individuals are not treated (unexposed). When treatment
is assigned randomly and there is perfect compliance to treatment assignment, such treatment
effects are identifiable and inference about the effect of treatment proceeds in a straightforward
fashion. On the other hand, if the treatment assignment mechanism is not known to the
analyst or compliance is not perfect, then these treatment effects are not identifiable from the
observable data.
A statistical parameter is considered identifiable if different values of the parameter give
rise to different probability distributions of the observable random variables. A parameter is
partially identifiable if more than one value of the parameter gives rise to the same observed
data law, but the set of such values is smaller than the parameter space. Traditionally, sta-
tistical inference has been restricted to the situation when parameters are identifiable. More
recent research has considered methods for conducting inference about partially identifiable
parameters. This research has been motivated to some extent by methods to evaluate causal
effects of treatment, which are frequently partially identifiable. For instance, causal estimands
are typically only partially identifiable in observational studies where the treatment selection
mechanism is not known to the analyst. Noncompliance in randomized trials may also render
treatment effects partially identifiable and a large amount of research has been devoted to
drawing inference about treatment effects in the presence of noncompliance. Partial identifi-
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ability also arises when drawing inference about treatment effects within principal strata or
effects describing relationships between an outcome and a treatment that are mediated by
some intermediate variable.
In order to conduct inference about treatment effects that are partially identifiable, two
approaches are often employed: (i) bounds are derived for the treatment effect under minimal
assumptions, or (ii) additional untestable assumptions are invoked under which the treat-
ment effect is identifiable and then sensitivity analysis is conducted to assess how inference
about the treatment effect changes as the untestable assumptions are varied. Below (i) and
(ii) are illustrated in five settings. In Section 2.2 we consider treatment effect bounds and
sensitivity analysis when the treatment assignment mechanism is unknown. In Section 2.3
partial identifiability of principal strata causal effects are discussed. In Section 2.4 the setting
of non-compliance is considered where there is interest in assessing the effect of treatment if
there was perfect compliance. In Section 2.5 bounds and sensitivity analysis for direct and
indirect effects in mediation analysis are presented, and in Section 2.6 longitudinal treatment
effects are considered. Much of the literature on bounds and sensitivity analysis focuses on
ignorance due to partial identifiability and tends to ignore uncertainty due to sampling er-
ror. Section 2.7 presents some methods that appropriately quantify this uncertainty when
drawing inference about partially identifiable treatment effects. Section 2.8 concludes with a
discussion.
2.2 Treatment Selection
2.2.1 Minimal Assumptions Bounds
Suppose we have a random sample of individuals where each potentially receives treatment
or control. Unless otherwise indicated, let Z indicate treatment received where Z = 1 denotes
treatment and Z = 0 denotes control. Denote the observed outcome of interest by Y . In
order to define a treatment effect on the outcome Y , we first define potential outcomes for an
individual when receiving treatment, denoted Y (1), and when receiving control, denoted Y (0).
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Throughout this paper we invoke the stable unit treatment value assumption (SUTVA; Rubin,
1980), i.e., there is no interference between units and there are no hidden (unrepresented)
forms of treatment such that each individual has two potential outcomes {Y (0), Y (1)}. The
no hidden forms of treatment guarantees that the observed outcome is equal to the potential
outcome corresponding to the observed treatment, namely that Y = Y (z) for Z = z. Here
this will be referred to as the causal consistency assumption; for further discussion of causal
consistency see Pearl (2010) and references therein. Once an individual receives treatment Z,
the potential outcome Y (Z) is observed and the other potential outcome (or counterfactual)
Y (1− Z) becomes missing. Assume that n iid copies of (Z, Y ) are observed and denoted by
(Zi, Yi) for i = 1, . . . , n.
In this section we consider treatment effect bounds when the treatment assignment mech-
anism is unknown. Here Z can be thought of as treatment selection by the individual or by
nature, rather than random treatment assignment as in an experiment. Define the average
treatment effect ATE to be E[Y (1)−Y (0)] = E[Y (1)]−E[Y (0)] where E denotes the expected
value. The ATE can be decomposed as
1∑
z=0
E[Y (1)|Z = z] Pr[Z = z]−
1∑
z=0
E[Y (0)|Z = z] Pr[Z = z]. (2.1)
Note E[Y (z)|Z = z] = E[Y |Z = z] by the causal consistency assumption. Thus from the
observed data E[Y (z)|Z = z] and Pr[Z = z] are identifiable and can be consistently estimated
by their empirical counterparts. On the other hand, the observed data provide no information
about E[Y (z)|Z = 1 − z], such that (2.1) is only partially identifiable without additional
assumptions.
Bounds on E[Y (1)−Y (0)] can be obtained by entertaining the smallest and largest possible
values for E[Y (z)|Z = 1−z]. If Y (1) and Y (0) are not bounded then bounds on E[Y (1)−Y (0)]
will be completely uninformative, ranging from −∞ to∞. Thus informative bounds are only
possible if Y (0) and Y (1) are bounded. Because any bounded variable can be rescaled to take
values in the unit interval, without loss of generality assume Y (z) ∈ [0, 1] for z = 0, 1. Then
0 ≤ E[Y (z)|Z = 1 − z] ≤ 1 and from (2.1) it follows that E[Y (1) − Y (0)] is bounded below
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by setting E[Y (1)|Z = 0] = 0 and E[Y (0)|Z = 1] = 1, which yields the lower bound
E[Y (1)|Z = 1] Pr[Z = 1]− E[Y (0)|Z = 0] Pr[Z = 0]− Pr[Z = 1]. (2.2)
Similarly E[Y (1) − Y (0)] is bounded above by setting E[Y (1)|Z = 0] = 1 and E[Y (0)|Z =
1] = 0, which yields the upper bound
E[Y (1)|Z = 1] Pr[Z = 1]− E[Y (0)|Z = 0] Pr[Z = 0] + Pr[Z = 0]. (2.3)
These bounds were derived independently by Robins (1989) and Manski (1990). The lower
and upper bounds (2.2) and (2.3) are sharp in the sense that it is not possible to derive
narrower bounds without additional assumptions. Note the interval formed by (2.2) and
(2.3) is contained in [−1, 1] and is of width 1. Thus the bounds are informative in that the
treatment effect is now restricted to half of the otherwise possible range [−1, 1]. On the other
hand, the bounds will always contain the null value 0 corresponding to no average treatment
effect. That is, without additional assumptions the sign of the treatment effect cannot be
determined from the observable data.
2.2.2 Additional Assumptions
The bounds (2.2) – (2.3) are sometimes called the “no assumptions” or “worst case”
bounds because no assumptions are made about the effect of treatment in the population
(Lee, 2005; Morgan and Winship, 2007). The only assumptions made in deriving (2.2) and
(2.3) are SUTVA and that the observed data constitute a random sample. If additional
assumptions are invoked, the treatment effect bounds may become tighter (i.e., narrower) or
even collapse to a point (i.e., the treatment effect may become identifiable). Sometimes these
additional assumptions will have implications that are testable based on the observed data.
Should the observed data provide evidence against an assumption under consideration, then
bounds should be computed without making this assumption.
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An example of an additional assumption is mean independence, i.e.,
E[Y (z)|Z = 0] = E[Y (z)|Z = 1] for z = 0, 1. (2.4)
Under (2.4) ATE is identifiable. Specifically the upper and lower bounds (2.2) and (2.3) both
equal E[Y (1)|Z = 1]−E[Y (0)|Z = 0], which is identifiable from the observable data and can
be consistently estimated by the “naive” estimator given by the difference in sample means
between the groups of individuals receiving treatment and control. Assumption (2.4) will
hold in experiments where treatment is randomly assigned as in a randomized clinical trial.
Moreover, in randomized experiments the stronger assumption
Y (z)q Z for z = 0, 1, (2.5)
will hold, which in turn implies (2.4).
In some settings it may be reasonable to consider additional assumptions that are not
as strong as (2.4) or (2.5) but nonetheless lead to tighter bounds than (2.2) and (2.3). For
example, monotonicity type assumptions might be considered, such as monotone treatment
selection (MTS)
E[Y (z)|Z = 1] ≥ E[Y (z)|Z = 0] for z = 0, 1. (2.6)
MTS assumes individuals who select treatment will on average have outcomes greater than or
equal to that of individuals who do not select treatment under the counterfactual scenario all
individuals selected the same z. Manski and Pepper (2000) consider MTS when examining the
effect of returning to school on wages later in life. For this example, MTS implies individuals
who choose to return to school will have higher wages on average compared to individuals
who choose to not return to school under the counterfactual scenario no individuals return
to school. Alternatively, one might assume monotone treatment response (MTR)
Pr[Y (1) ≥ Y (0)] = 1
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(Manski, 1997). MTR assumes that under treatment each individual will have a response
greater than or equal to that under control. For instance, suppose Z = 1 if an individual elects
to get the annual influenza vaccine and Z = 0 otherwise, and let Y (z) = 1 if an individual
subsequently does not develop flu-like symptoms when Z = z, and Y (z) = 0 otherwise. MTR
asserts that each individual is more or as likely to not develop flu-like symptoms if they are
vaccinated versus if they are unvaccinated. Given to date there is no evidence that the annual
flu vaccine enhances the probability of acquiring influenza, MTR might be plausible for this
example.
Assuming MTS or MTR can lead to narrower bounds than (2.2) and (2.3) because they
imply additional constraints on unobserved counterfactual expectations. For example, assum-
ing MTS, E[Y (0)|Z = 1] is bounded below by E[Y (0)|Z = 0] and E[Y (1)|Z = 0] is bounded
above by E[Y (1)|Z = 1], implying the upper bound on E[Y (1)− Y (0)] is
E[Y (1)|Z = 1]− E[Y (0)|Z = 0], (2.7)
for which the naive estimator is consistent. Under MTS the lower bound remains (2.2). In
contrast to the no assumptions bounds, assuming MTS the bounds may exclude 0, specifically
when (2.7) is negative. MTR implies E[Y (1)] ≥ E[Y (0)] which in turn implies that the ATE
lower bound is 0. Under MTR the upper bound remains (2.3).
2.2.3 AZT Example
To illustrate the bounds above consider a hypothetical study of 2000 HIV patients (from
Figure 2 of Robins, 1989) where 1400 individuals elected to take the drug AZT and 600
elected not to take AZT (this is a simplified version of the problem Robins considers). The
outcome of interest is death or survival at a given time point. Of the 2000 patients, 1000 died
with exactly 500 from each group. Let Z = 1 if the patient elected to take AZT and Z = 0
otherwise; let Y = 1 if the individual died and 0 otherwise. The naive estimator, i.e., the
difference in sample means between Z = 1 and Z = 0, equals 500/1400-500/600 ≈ -0.48. The
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empirical estimates of the no assumptions bounds (2.2) and (2.3) equal −0.7 and 0.3. In this
setting, the MTS assumption (2.6) supposes that individuals who elected to take AZT would
have been more or as likely to die as individuals who did not take AZT in the counterfactual
scenarios where everyone receives treatment or everyone does not receive treatment. This
might be reasonable if it is thought that those who took AZT were on average less healthy
than those who did not. Assuming MTS, the upper bound (2.7) is estimated to be -0.48. Thus
in this example the MTS bounds are substantially tighter than the no assumption bounds.
The estimated MTS bounds lead to the conclusion (ignoring sampling variability, a point
which we return to later) that AZT reduces the probability of death by at least 0.48 whereas
without the MTS assumption we cannot even conclude whether the effect of treatment is
non-zero.
2.2.4 Sensitivity Analysis
Assumptions such as (2.4) or (2.5) which identify the ATE, or assumptions such as MTS
which sharpen the bounds, cannot be tested empirically because such assumptions pertain
to the counterfactual distribution of Y (z) given Z = 1 − z. Robins and others (e.g., see
Robins et al., 1999; Scharfstein et al., 1999) have argued that a data analyst should conduct
sensitivity analysis to explore how inference varies as a function of departures from any
untestable assumptions.
For instance, a departure from assumption (2.5) might be due to the existence of an
unmeasured variable U associated with both treatment selection Z and the potential outcomes
Y (z) for z = 0, 1; a variable such as U is often referred to as an unmeasured confounder. Under
this scenario, one might postulate that Y (z)qZ|U for z = 0, 1 rather than (2.5). Sensitivity
analysis proceeds by examining how inference drawn about ATE varies as a function of the
magnitude of the association of U with Z, Y (0), and Y (1). This idea has roots as early
as Cornfield et al. (1959), who demonstrated the plausibility of a causal effect of cigarette
smoking (Z) on lung cancer (Y ) by arguing that the absence of such a relationship was only
possible if there existed an unmeasured factor U associated with cigarette use that was at
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least as strongly associated with lung cancer as cigarette use. This idea was further developed
by Schlesselman (1978); Rosenbaum and Rubin (1983); Lin et al. (1998); Herna´n and Robins
(1999); and VanderWeele and Arah (2011) among others.
To illustrate this approach, suppose in the AZT example above that the analyst first
assumes (2.5) holds and thus estimates the effect of AZT to be -0.48. To proceed with
sensitivity analysis, the analyst posits the existence of an unmeasured binary variable U and
assumes that Y (z)q Z|U for z = 0, 1. Similar to VanderWeele and Arah (2011), let
c(z) = {E[Y (z)|U = 1]− E[Y (z)|U = 0]}{Pr[U = 1|Z = z]− Pr[U = 1]}.
Then under the assumption that Y (z) q Z|U for z = 0, 1, the naive estimator converges in
probability to E[Y (1)] − E[Y (0)] + c(1) − c(0). Thus the naive estimator is asymptotically
unbiased if and only if c(1) = c(0). For an alternative decomposition of the asymptotic bias
of the naive estimator see Morgan and Winship (2007, §2.6.3)
Sensitivity analysis proceeds by making varying assumptions about the unidentifiable
associations of U with Y (0), Y (1), and Z. Under the most extreme of these assumptions
the bounds (2.2) and (2.3) are recovered. In particular, the upper bound in (2.3) is achieved
when Pr[U = 1|Z = 1] = 0, Pr[U = 1|Z = 0] = 1, E[Y (1)|U = 1] = 1 and E[Y (0)|U = 0] = 0,
meaning that the confounder U is perfectly negatively correlated with treatment Z and that if
the confounder is present (U = 1), then a treated individual will die, whereas if the confounder
is absent (U = 0), then an untreated individual will survive. The lower bound (2.2) is achieved
under the opposite conditions.
In practice the extreme associations of U with Y (0), Y (1), and Z leading to the bounds
might be considered unrealistic. Instead the analyst might consider associations only in a
range deemed plausible by subject matter experts. In order to arrive at an accurate range,
care should be taken in communicating the meaning of these associations and eliciting this
range should be done in a manner that avoids data driven choices. Alternatively, the degree
of associations required to change the sign of the effect of interest might be determined. For
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instance, suppose the analyst further assumes that E[Y (z)|U = 1] − E[Y (z)|U = 0] does
not depend on z. This assumption will hold if the effect of Z on Y is the same if U = 0
or U = 1. Letting γ0 = E[Y (z)|U = 1] − E[Y (z)|U = 0] and γ1 = Pr[U = 1|Z = 1] −
Pr[U = 1|Z = 0], the asymptotic bias of the naive estimator is then given by γ0γ1 and a bias
adjusted estimator is found by subtracting γ0γ1 from the naive estimator. Sensitivity analysis
may proceed by determining the values of γ0 and γ1 for which the bias adjusted estimator of
the ATE will have the opposite sign of the naive estimator. For the AZT example, the bias
adjusted estimator will have the opposite sign of the naive estimator if γ0γ1 < −0.48. This
indicates that the product of (i) the difference in the mean potential outcomes between levels
of the confounder for both treatment and control and (ii) the difference in the prevalence of
the unmeasured confounder between the treatment and control groups must be less than -
0.48. Such magnitudes might be considered unlikely in the opinion of subject matter experts,
in which case the sensitivity analysis would support the existence of a beneficial effect of
AZT on survival among HIV+ men (ignoring sampling variability). Note the observed data
distribution places some restrictions on the possible values of (γ0, γ1), i.e., (γ0, γ1) is partially
identifiable. For instance, if γ1 = 1 then Pr[U = 1|Z = 1] = 1 and Pr[U = 1|Z = 0] = 0 which
implies E[Y (z)|U = u] = E[Y (z)|Z = u] and therefore max{E[Y (1)|Z = 1]−1,−E[Y (0)|Z =
0]} ≤ γ0 ≤ min{E[Y (1)|Z = 1], 1 − E[Y (0)|Z = 0]}. Such considerations should be taken
into account when determining the range of values of (γ0, γ1) in sensitivity analysis.
Because the data provide no evidence about U , VanderWeele (2008) and VanderWeele
and Arah (2011) recommend choosing U and any simplifying assumptions based on what is
considered plausible by relevant subject-matter experts. Such sensitivity analyses are most
applicable when the existence of unmeasured confounders is known, but these factors could
not be measured for logistical or other reasons. General bias formulas to be used for sensitivity
analyses of unmeasured confounding for categorical or continuous outcomes, confounders, and
treatments can be found in VanderWeele and Arah (2011).
In other settings there might not be any known unmeasured confounders, or it may be
thought that there are numerous unmeasured confounders, in which cases the sensitivity
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analysis strategy described above would not be applicable or feasible. One general alternative
approach entails making additional untestable assumptions regarding the unobserved poten-
tial outcome distributions. Typically these assumptions (or models) are indexed by one or
more sensitivity analysis parameters conditional upon which the causal estimand of interest
is identifiable (e.g., Scharfstein et al., 1999; Brumback et al., 2004). Sensitivity analysis then
proceeds by examining how inference changes as assumed values of the parameters are varied
over plausible ranges. Examples of such sensitivity analyses are given below in Sections 2.3.4
and 2.6.3.
2.2.5 Covariate Adjustment
Typically in observational studies baseline (pre-treatment) covariates X will be collected
in addition to Z and Y . Incorporating information from observed covariates can help sharpen
inferences about partially identified treatment effects. For example, incorporating covariates
will generally lead to narrower bounds (Scharfstein et al., 1999). This follows because any
treatment effect consistent with the distribution of observed variables (X,Y, Z) must also be
consistent with the distribution of (Y, Z), i.e., the observable variables if we do not observe or
choose to ignore X (Lee, 2009). Covariate adjusted bounds are discussed further in Section
2.3.3 below.
Additionally, incorporating covariates may lend plausibility to some of the bounding as-
sumptions discussed in Section 2.2.2. For example, in the absence of randomized treatment
assignment (2.4) or (2.5) may be dubious. Instead of (2.4) it might be more plausible to
assume
E[Y (z)|Z = 0, X = x] = E[Y (z)|Z = 1, X = x] for z = 0, 1. (2.8)
Similarly, assumption (2.5) might be replaced by
Y (z)q Z|X for z = 0, 1, (2.9)
i.e., each potential outcome is independent of treatment selection conditional on some set
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of covariates. Assumption (2.9) is commonly referred to as no unmeasured confounders.
Assumptions such as (2.8) or weaker inequalities similar to (2.6) such as
E[Y (z)|Z = 1, X = x] ≥ E[Y (z)|Z = 0, X = x] for z = 0, 1,
may be deemed plausible for certain levels of X, but not for others. Availability of covariates
also allows for the consideration of new types of assumptions (e.g., see Chiburis, 2010).
To conduct covariate adjusted sensitivity analysis, departures from identifying assump-
tions such as (2.9) can be explored. Similar to the previous section, a departure from (2.9)
might entail positing the existence of an unmeasured variable U associated with both treat-
ment selection Z and the potential outcomes Y (z) for z = 0, 1. Under this scenario, one
might postulate that Y (z) q Z|{X,U} for z = 0, 1 rather than (2.9) and sensitivity analysis
proceeds by examining how inference varies as a function of the magnitude of the association
of U with Z, Y (0), and Y (1) given X. Similar to covariate adjusted bounds, smaller associ-
ations or tighter regions of the values of the sensitivity parameters may be deemed plausible
within certain levels of X, potentially yielding sharper inferences from the sensitivity analy-
ses. However, as cautioned by Robins (2002), care should be taken in clearly communicating
the meaning of such sensitivity parameters and their relationship to covariates when eliciting
plausible ranges from subject matter experts. In some scenarios plausible regions for sensi-
tivity parameters may in fact be wider when conditioning on X than when not conditioning
on X.
2.3 Principal Stratification
2.3.1 Background
Even if treatment is randomly assigned (e.g., as in a clinical trial), the causal estimand of
interest may still be only partially identifiable. For example, in many studies it is often of in-
terest to draw inference about treatment effects on outcomes that only exist or are meaningful
after the occurrence of some observable intermediate variable. For instance, in studies where
23
some individuals die, investigators might be interested in treatment effects only among indi-
viduals alive at the end of the study. Unfortunately, estimands defined by contrasting mean
outcomes under treatment and control that simply condition on this observable intermediate
variable do not measure a causal effect of treatment without additional assumptions. One
approach that may be employed in this scenario entails principal stratification (Frangakis
and Rubin, 2002). Principal stratification uses the potential outcomes of the intermediate
post-randomization variable to define strata of individuals. Because these “principal strata”
are not affected by treatment assignment, treatment effect estimands defined within princi-
pal strata have a causal interpretation and do not suffer from the complications of standard
post-randomization adjusted estimands. The simple framework of principal stratification has
a wide range of applications. For a recent discussion of the utility (and lack thereof) of
principal stratification, see Pearl (2011) and corresponding reader reactions.
As a motivating example for this section, we consider evaluating vaccine effects on post-
infection outcomes. In vaccine studies, uninfected subjects are enrolled and followed for
infection endpoints, and infected subjects are subsequently followed for post-infection out-
comes such as disease severity or death due to infection with the pathogen targeted by the
vaccine; often interest is in assessing the effect of vaccination on these post-infection endpoints
(Hudgens and Halloran, 2006). For example, Preziosi and Halloran (2003) present data from
a pertussis vaccine field study in Niakhar, Senegal. In this study 3845 vaccinated children and
1020 unvaccinated children were followed for one year for pertussis. In the vaccine group 548
children contracted pertussis, of whom 176 had severe infections; in the unvaccinated group
206 children contracted pertussis, of whom 129 had severe infections. In this setting investi-
gators are interested in assessing whether or not the vaccine had an effect on the severity of
infection.
When assessing such post-infection effects, a data analyst might consider contrasts be-
tween study arms including all individuals randomized, or, alternatively, only those who
become infected. Though including all individuals in the study has the advantage of provid-
ing valid inference about the overall effect of vaccination (assuming perfect compliance), such
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an approach does not distinguish vaccine effects on susceptibility to infection from effects on
the post-infection endpoint of interest. An analysis that conditions on infection attempts to
distinguish these effects and may be more sensitive in detecting post-infection vaccine effects.
However, because the set of individuals who would become infected under control are not
likely to be the same as those who would become infected if given the vaccine, conditioning
on infection might result in selection bias. For example, those who would become infected un-
der vaccine may tend to have weaker immune systems than those who would become infected
under control, and thus are more susceptible to severe infection. Because of this potential
selection bias, comparisons between infected vaccinees and infected controls do not necessarily
have causal interpretations.
2.3.2 Principal Effects
In this section treatment is vaccination, with Z = 1 corresponding to vaccination and
Z = 0 corresponding to not being vaccinated. Assume that assignment to vaccine is equivalent
to receipt of vaccine, i.e., there is no non-compliance. Denote the potential infection outcome
by S(z), where S(z) = 0 if uninfected and S(z) = 1 if infected. Here the focus is on evaluating
the causal effect of vaccine on Y, a post-infection outcome. For simplicity we consider the
case where Y is binary, indicating the presence of severe disease. If S(z) = 1, define the
potential post-infection outcome Y (z) = 1 if the individual would have the worse (or more
severe) post-infection outcome of interest given z, and Y (z) = 0 otherwise. If an individual’s
potential infection outcome for treatment z is uninfected, (i.e., S(z) = 0), then we adopt
the convention that Y (z) is undefined. In other words, it does not make sense to define the
severity of an infection in an individual who is not infected. This convention is similar to that
employed in other settings. For instance, in the analysis of quality of life studies it might be
assumed that quality of life metrics are not well defined in those who are not alive (Rubin,
2000).
Define a basic principal stratification P0 according to the joint potential infection outcomes
SP0 = (S(0), S(1)). The four basic principal strata or response types are defined by the
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joint potential infection outcomes, (S(0), S(1)), and are composed of immune (not infected
under both vaccine and placebo), harmed (infected under vaccine but not placebo), protected
(infected under placebo but not vaccine), and doomed individuals (infected under both vaccine
and placebo). Note the only stratum where both potential post-infection endpoints are well
defined is in the doomed basic principal stratum, SP0 = (1, 1). Thus defining a post-infection
causal vaccine effect is only possible in the doomed principal stratum SP0 = (1, 1). Such a
causal estimand will describe the effect of vaccination on disease severity in individuals who
would become infected whether vaccinated or not. For instance, the vaccine effect on disease
severity may be defined by
E[Y (1)|SP0 = (1, 1)]− E[Y (0)|SP0 = (1, 1)]. (2.10)
Frangakis and Rubin call treatment effect estimands such as (2.10) “principal effects.”
2.3.3 Bounds
Assume we observe n iid copies of (Z, S, Y ) denoted by (Zi, Si, Yi) for i = 1, . . . , n. Also
assume that the doomed principal strata is non-empty, Pr[SP0 = (1, 1)] > 0, so that the
principal effect in (2.10) is well defined. Bounds for (2.10) are presented below under two
additional assumptions: independent treatment assignment, i.e.,
Z q {Y (z), S(z)} for z = 0, 1 (2.11)
and monotone treatment response with respect to S, i.e.,
Pr[S(0) ≥ S(1)] = 1. (2.12)
Assumption (2.11) will hold in randomized vaccine trials. Monotonicity (2.12) assumes that
the vaccine does no harm at the individual level, i.e., there are no individuals who would be
infected if vaccinated but uninfected if not vaccinated. Monotonicity is equivalent to assuming
the harmed principal stratum is empty. Note no such monotonicity assumption is being made
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regarding Y . Under (2.11), assumption (2.12) implies P (S = 1|Z = 1) ≤ P (S = 1|Z = 0),
which is testable using the observed data. For the pertussis example, the proportion infected
in the vaccine group was less than in the unvaccinated group; thus, assuming (2.11), the data
do not provide evidence against (2.12).
Assuming independent treatment assignment and monotonicity, (2.10) is partially identi-
fiable from the observable data. The left term of (2.10) can be written
E[Y (1)|SP0 = (1, 1)] = E[Y (1)|S(1) = 1]
= E[Y (1)|S(1) = 1, Z = 1]
= E[Y |S = 1, Z = 1],
(2.13)
where the first equality holds under (2.12), the second equality under (2.11), and the third by
causal consistency. On the other hand, the right term of (2.10) is only partially identifiable.
To see this, note
E[Y (0)|S(0) = 1] = E[Y (0)|SP0 = (1, 1)] Pr[S(1) = 1|S(0) = 1]+
E[Y (0)|SP0 = (1, 0)] Pr[S(1) = 0|S(0) = 1].
(2.14)
In (2.14), only E[Y (0)|S(0) = 1] and Pr[S(1) = s|S(0) = 1] for s = 0, 1 are identifiable. In
particular, E[Y (0)|S(0) = 1] = E[Y |S = 1, Z = 0] by similar reasoning to (2.13), and
Pr[S(1) = 1|S(0) = 1] = Pr[S(1) = 1]
Pr[S(0) = 1]
=
Pr[S = 1|Z = 1]
Pr[S = 1|Z = 0] ,
where the first equality holds under (2.12) and the second under independent treatment as-
signment (and causal consistency). The other two terms in (2.14), namely E[Y (0)|SP0 =
(1, 1)] and E[Y (0)|SP0 = (1, 0)], are only partially identifiable. In words, infected controls
are a mixture of individuals in the protected and doomed principal stratum and without
further assumptions the observed data do not identify exactly which infected controls are
doomed. Therefore the probability of severe disease when not vaccinated in the doomed
principal stratum is not identified. Under (2.12), the data do however indicate what propor-
tion of infected controls are doomed and this information provides partial identification of
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E[Y (0)|SP0 = (1, 1)] and hence (2.10).
For fixed values of E[Y (0)|S(0) = 1] and Pr[S(1) = 1|S(0) = 1], any pair of expectations
(E[Y (0)|SP0 = (1, 1)], E[Y (0)|SP0 = (1, 0)]) ∈ [0, 1]2 satisfying (2.14) will give rise to the same
observed data distribution. Equation (2.14) describes a line segment with non-positive slope
intersecting the unit square as illustrated in Figure 1. An upper bound of E[Y (0)|SP0 = (1, 1)]
and thus a lower bound for (2.10) is achieved when the line intersects the right or lower side
of the square, i.e., when either
E[Y (0)|SP0 = (1, 1)] = 1 or E[Y (0)|SP0 = (1, 0)] = 0. (2.15)
Together (2.14) and (2.15) imply E[Y (0)|SP0 = (1, 1)] is bounded above by
min
{
1,
E[Y (0)|S(0) = 1]
Pr[S(1) = 1|S(0) = 1]
}
. (2.16)
Similarly, E[Y (0)|SP0 = (1, 1)] is bounded below by
max
{
0,
E[Y (0)|S(0) = 1]− Pr[S(1) = 0|S(0) = 1]
Pr[S(1) = 1|S(0) = 1]
}
. (2.17)
Combining (2.17) with (2.13) yields the upper bound on the principal effect of interest (2.10)
and combining (2.16) with (2.13) yields the lower bound. These bounds were derived by
Rotnitzky and Jemiai (2003); Zhang and Rubin (2003); and Hudgens et al. (2003). Con-
sistent estimates of (2.16) and (2.17) can be computed by replacing E[Y (0)|S(0) = 1] with∑
i YiI(Si = 1, Zi = 0)/
∑
i I(Si = 1, Zi = 0) and Pr[S(1) = 1|S(0) = 1] with
min
{
1,
∑
i I(Si = Zi = 1)/
∑
i I(Zi = 1)∑
i I(Si = 1, Zi = 0)/
∑
i I(Zi = 0)
}
.
Returning to the pertussis vaccine study, the estimated lower and upper bounds of (2.10) are
-0.57 and -0.15. These estimated bounds exclude zero, leading to the conclusion (ignoring
sampling variability) that vaccination lowers the risk of severe pertussis in individuals who
will become infected regardless of whether they are vaccinated.
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Note if Pr[S(1) = 1|S(0) = 1] = 1, i.e., the vaccine has no protective effect against
infection, then the protected principal stratum SP0 = (1, 0) is empty and both (2.16) and
(2.17) equal E[Y (0)|S(0) = 1] meaning that (2.10) is identifiable and equals E[Y |Z = 1, S =
1]− E[Y |Z = 0, S = 1]. Intuitively the lack of vaccine effect against infection eliminates the
potential for selection bias.
As discussed in Section 2.2.5, incorporation of covariates can tighten bounds. For covari-
ates X with finite support, one simple approach of adjusting for covariates entails determining
bounds within strata defined by the levels of X and then taking a weighted average of the
within strata bounds over the distribution of X. For the bounds in (2.16) and (2.17), adjust-
ment for covariates will always lead to bounds that are at least as tight as bounds unadjusted
for covariates (Lee, 2009; Long and Hudgens, 2013).
If the observed data provide evidence contrary to monotonicity (2.12), then bounds may be
obtained under only (2.11). Without monotonicity (2.12) the proportion of infected controls
that are in the doomed principal stratum is no longer identified but may be bounded in order to
arrive at bounds for E[Y (0)|SP0 = (1, 1)]. In addition, the harmed principal stratum defined
by SP0 = (0, 1) is no longer empty and thus E[Y (1)|SP0 = (1, 1)] is no longer identifiable
from the observed data and may also be bounded in a similar fashion to E[Y (0)|SP0 = (1, 1)].
Details regarding these bounds without the monotonicity assumption may be found in Zhang
and Rubin (2003) and Grilli and Mealli (2008).
2.3.4 Sensitivity Analysis
The bounds (2.16) and (2.17) are useful in bounding the vaccine effect on Y in the doomed
stratum. However, these bounds may be rather extreme. An alternative approach is to
make an untestable assumption that identifies the post-infection vaccine effect on Y and then
consider how sensitive the resulting inference is to departures from this assumption. For
instance, assuming
Pr[Y (0) = 1|SP0 = (1, 1)] = Pr[Y (0) = 1|SP0 = (1, 0)], (2.18)
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identifies (2.10). Hudgens and Halloran (2006) refer to this as the no selection model. To
examine how inference varies according to departures from (2.18), following Scharfstein et al.
(1999), and Robins et al. (1999), consider the following sensitivity parameter
exp(γ) =
Pr[Y (0) = 1|SP0 = (1, 1)]/Pr[Y (0) = 0|SP0 = (1, 1)]
Pr[Y (0) = 1|SP0 = (1, 0)]/Pr[Y (0) = 0|SP0 = (1, 0)] . (2.19)
In words, exp(γ) compares the odds of severe disease when not vaccinated in the doomed
versus the protected principal stratum. Assuming (2.18) corresponds to γ = 0. A sensitivity
analysis entails examining how inference about (2.10) varies as γ becomes farther from 0. For
any fixed value of γ, (2.10) is identified (see Figure 1) and can be consistently estimated by
maximum likelihood estimation without any additional assumptions (Gilbert et al., 2003).
The lower and upper bounds (2.17) and (2.16) are obtained by letting γ →∞ and γ → −∞.
To see this, note that as γ →∞ (2.19) implies in the limit that either
Pr[Y (0) = 1|SP0 = (1, 1)] = 1 or Pr[Y (0) = 1|SP0 = (1, 0)] = 0,
which is equivalent to (2.15). Sensitivity analysis can be conducted by letting γ range over a
set of values Γ.
Tighter bounds can be achieved by placing restrictions on Γ, perhaps based on prior beliefs
about γ elicited from subject matter experts. For example, Shepherd et al. (2007) surveyed
10 recognized HIV experts in order to elicit a plausible range for a sensitivity parameter
representing a departure from the assumption of no selection bias between vaccinated and
unvaccinated individuals who acquired HIV during an HIV vaccine trial. Included in this
survey was the analysis approach, a brief explanation of the potential for selection bias, the
definition of the sensitivity parameter being employed, examples of the implications of certain
sensitivity parameter values on selection bias, and possible justification for believing certain
values of the sensitivity parameter. The expert responses to the survey were fairly consistent
and several written justifications for the respondents’ chosen ranges indicated a high level of
understanding of both the counterfactual nature of the sensitivity parameter and the need to
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account for selection bias.
2.4 Randomized Studies with Partial Compliance
2.4.1 Global Average Treatment Effect
In a placebo controlled randomized trial where (2.5) holds but there is non-compliance
(i.e., individuals are randomly assigned to treatment or control but they do not necessarily
adhere or comply with their assigned treatment), the naive estimator is a consistent estimator
of the average effect of treatment assignment. However, in this case parameters other than
the effect of treatment assignment may be of interest. As in the last section, a principal effect
may be defined using compliance as the intermediate post-randomization variable over which
to define principal strata; namely the principal strata would consist of individuals who would
comply with their randomization assignment if assigned treatment or control or “compliers,”
individuals who would always take treatment regardless of randomization or “always takers,”
individuals who never take treatment “never takers,” and individuals who take treatment
only if assigned control or “defiers.” A principal effect of interest might be the effect of
treatment in the complier principal stratum (Imbens and Angrist, 1994; Angrist et al., 1996),
in which case bounds and sensitivity analyses similar to those in Section 2.3 are applicable.
However, as several authors including Robins (1989) and Robins and Greenland (1996) have
pointed out, such principal effects may not be of ultimate public health interest because they
only apply to the subpopulation of compliers in clinical trials, which may differ from the
population that elect to take treatment once licensed. For example, once efficacy is proved,
a larger subpopulation of people may be willing to take the treatment. Effects defined on
the subpopulation of compliers are also of limited decision-making utility because individual
principal stratum membership is generally unknown prior to treatment assignment (Joffe,
2011).
Robins and Greenland (1996) suggested that in settings where the trial population could
be persuaded to take the treatment once licensed, a more relevant public health estimand is
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the global average treatment effect, defined as the average effect of actually taking treatment
versus not taking treatment given treatment assignment z. This causal estimand is similar
to the average treatment effect defined in Section 2.2, but requires generalizing the potential
outcome definitions used previously to include separate potential outcomes for each of the four
combinations of treatment assignment and actual treatment received. For further discussion
regarding causal models in presence of noncompliance see Chickering and Pearl (1996) and
Dawid (2003) among others.
Suppose we observe data from a clinical trial where each individual is randomly assigned
to treatment or control. Let Z indicate treatment assignment where Z = 1 denotes treat-
ment and Z = 0 denotes control. Suppose individuals do not necessarily comply with their
randomization assignment and let S be a variable indicating whether or not treatment was
actually taken, where S = 1 denotes treatment was taken and S = 0 otherwise. Thus an
individual is compliant with their randomization assignment if S = Z. Let Y be a binary
outcome of interest. Denote the potential treatment taken by S(z) for z = 0, 1, where
S(z) = 1 indicates taking treatment when assigned treatment z and S(z) = 0 denotes not
taking treatment when assigned z. Let Y (z, s) denote the potential outcome if an individual
is assigned treatment z but actually takes treatment s. Conceiving of these potential out-
comes depends on a supposition that trial participants who did not comply in the trial could
be persuaded to take the treatment under other circumstances. Given this supposition, the
global average treatment effect for each treatment assignment z = 1 and z = 0 is defined as
GATEz = E[Y (z, 1)−Y (z, 0)]. For instance, GATE1 is the difference in the average outcomes
under the counterfactual scenario everyone was assigned vaccine and did comply versus the
counterfactual scenario everyone was assigned vaccine but did not comply.
Bounds for GATEz are given below under three assumptions: independent treatment
assignment
Z q {S(0), S(1), Y (0, 0), Y (0, 1), Y (1, 0), Y (1, 1)}; (2.20)
monotonicity with respect to S
Pr[S(1) ≥ S(0)] = 1; (2.21)
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and the exclusion restriction
Y (0, s) = Y (1, s) for s = 0, 1. (2.22)
Assumption (2.22) indicates treatment assignment has no effect when the actual treatment
taken is held fixed. Under (2.22), GATE0 = GATE1 which we denote by GATE. In this
case each individual has two potential outcomes according to s = 0 and s = 1 (which could
be denoted by Y (s) = Y (0, s) = Y (1, s) for s = 0, 1) and GATE is equivalent to the ATE
discussed in Section 2.2 with z replaced by s. Robins (1989) derived bounds for GATE
under several different combinations of (2.20) – (2.22) as well as some additional assumptions
such as monotonicity with respect to S, i.e., Y (z, 1) ≥ Y (z, 0) for z = 0, 1. Manski (1990)
independently derived related results. Under (2.20) – (2.22) the sharp lower and upper bounds
on GATE are
− 1 + maxz{Pr[Y = 1, S = 1|Z = z]}+ maxz{Pr[Y = 0, S = 0|Z = z]}, (2.23)
and
1−maxz{Pr[Y = 0, S = 1|Z = z]} −maxz{Pr[Y = 1, S = 0|Z = z]}. (2.24)
Balke and Pearl (1997) derived sharp bounds for GATE under a variety of assumptions,
including (2.20) – (2.22), by recognizing that the derivation of the bounds is equivalent to
a linear programming optimization problem. To see that bounds can be formulated as a
linear programming optimization problem, first note that GATE can be expressed as a linear
combination of probabilities of the joint distribution of L = (Y (0, 0), Y (0, 1), Y (1, 0), Y (1, 1),
S(0), S(1)) ∑
l1∈L1
Pr[L = l1]−
∑
l0∈L0
Pr[L = l0] (2.25)
where Ls is the set of possible realizations of L where Y (0, s) = Y (1, s) = 1 for s = 0, 1.
Under independent treatment assignment, there exists a linear transformation between the
probabilities in the joint distribution of L and the probabilities in the conditional distribution
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of the observable random variables Y and S given Z, namely
Pr[Y = y, S = s|Z = z] =
∑
l∈Oys·z
Pr[L = l] (2.26)
where Oys·z is the set of possible realizations of L where S(z) = s and Y (z, s) = y for z, y, s =
0, 1. To find the sharp bounds, the objective function (2.25) is minimized (or maximized)
subject to the constraints (2.26), Pr[L = l] ≥ 0 for every l ∈ L, and ∑l∈L Pr[L = l] = 1
where L is the set of all possible realizations of L assuming (2.21) and (2.22). Optimization
may be accomplished using the simplex algorithm and the dimension of this problem permits
obtaining a closed form solution involving probabilities of the observed data distribution
(Balke and Pearl, 1993), namely (2.23) and (2.24).
If in addition to assumptions (2.20) and (2.22), it is assumed that
E[Y (z, 1)− Y (z, 0)|Z = 1, S = s] = E[Y (z, 1)− Y (z, 0)|Z = 0, S = s] (2.27)
for s, z = 0, 1 then GATE is identified and equals
E[Y |Z = 1]− E[Y |Z = 0]
E[S|Z = 1]− E[S|Z = 0] (2.28)
(Herna´n and Robins, 2006). For s = 0 assumption (2.27) is known as a no current treatment
interaction assumption (Robins, 1994), and expression (2.28) is known as the instrumental
variables estimand (Imbens and Angrist, 1994; Angrist et al., 1996). Sensitivity analyses may
be conducted by defining sensitivity parameters representing departures from (2.20), (2.22)
or (2.27) and then examining how inference about GATE varies as values of these parameters
change. For instance, Robins et al. (1999) define current treatment interaction functions
which represent a departure from (2.27) for s = 0.
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2.4.2 Cholestyramine Example
To illustrate the GATE, we consider data presented in Pearl (2009, §8.2.6) on 337 subjects
who participated in a randomized trial to assess the effect of cholestyramine on cholesterol
reduction. Let Z = 1 denote assignment to cholestyramine and Z = 0 assignment to placebo.
Let S = 1 if cholestyramine was actually taken by the participant and S = 0 otherwise. Let
Y = 1 if the participant had a response and Y = 0 otherwise, where response is defined as
reduction in the level of cholesterol by 28 units or more. Pearl reported the following observed
proportions
Pˆr[Y = 0, S = 0|Z = 0] = 0.919 Pˆr[Y = 0, S = 0|Z = 1] = 0.315
Pˆr[Y = 0, S = 1|Z = 0] = 0.000 Pˆr[Y = 0, S = 1|Z = 1] = 0.139
Pˆr[Y = 1, S = 0|Z = 0] = 0.081 Pˆr[Y = 1, S = 0|Z = 1] = 0.073
Pˆr[Y = 1, S = 1|Z = 0] = 0.000 Pˆr[Y = 1, S = 1|Z = 1] = 0.473
No participants assigned placebo actually took cholestyramine, suggesting the monotonicity
assumption (2.21) is reasonable. On the other hand, 38.8% of individuals assigned treatment
did not actually take cholestyramine.
From (2.23) and (2.24) the bounds on GATE assuming (2.21), (2.20) and (2.22) are
estimated to be −1+max{0.000, 0.473}+max{0.919, 0.315} = 0.392 and 1−max{0, 0.139}−
max{0.081, 0.073} = 0.780. The positive sign of the estimated bounds indicates the treatment
is beneficial. Pearl interprets the estimated bounds as follows: “although 38.8% of the subjects
deviated from their treatment protocol, the experimenter can categorically state that, when
applied uniformly to the population, the treatment is guaranteed to increase by at least
39.2% the probability of reducing the level of cholesterol by 28 points or more.” Such an
interpretation does not account for sampling variability, the topic of Section 2.7.
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2.5 Mediation Analysis
2.5.1 Natural Direct and Indirect Effects
As demonstrated in Sections 2.3 and 2.4, independent treatment assignment does not
guarantee that the causal estimand of interest will be identifiable. Another setting where this
occurs is in mediation analysis, where researchers are interested in whether or not the effect
of a treatment is mediated by some intermediate variable. Even in studies where treatment
is assigned randomly and there is perfect compliance, confounding may exist between the
intermediate variable and the outcome of interest such that effects describing the mediated
relationships will not in general be identifiable. Thus bounds and sensitivity analysis may be
helpful in drawing inference.
To illustrate, let Y be an observed binary outcome of interest, and S a binary intermediate
variable observed some time between treatment assignment Z and the observation of Y . The
goal is to assess whether and to what extent the effect of Z on Y is mediated by or through
S. Denote the potential outcome of the intermediate variable under treatment z by S(z) for
z = 0, 1 such that S = S(Z), and the potential outcomes under treatment z and intermediate
s as Y (z, s) such that Y = Y (Z, S(Z)). Here, as in the previous section, it is assumed that
both Z and S can be set to particular fixed values, such that there are four potential outcomes
for Y per individual. Unless otherwise specified, independent treatment assignment (2.20)
will be assumed throughout this section.
Define the total effect of treatment to be E[Y (1, S(1)) − Y (0, S(0))], which is equivalent
to the ATE defined in Section 2.2.1. The total effect of treatment can be decomposed in the
following way
E[Y (1, S(1))− Y (0, S(0))] = E[Y (1, S(z))− Y (0, S(z))]
+ E[Y (z′, S(1))− Y (z′, S(0)]
(2.29)
for z = 0, 1 and z′ = 1−z. The right side of (2.29) decomposes the total effect into the sum of
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two separate effects. The first expectation on the right side of (2.29) is the natural direct effect
for treatment z, NDEz = E[Y (1, S(z))−Y (0, S(z))] (Robins and Greenland, 1992; Pearl, 2001;
Robins, 2003; Kaufman et al., 2009; Robins and Richardson, 2010). The natural direct effect
is the average effect of the treatment on the outcome when the intermediate variable is set to
the potential value that would occur under treatment assignment z. The second expectation
on the right side of (2.29) is the natural indirect effect, NIEz = E[Y (z, S(1)) − Y (z, S(0))]
(Pearl, 2001; Robins, 2003; Imai et al., 2010). The natural indirect effect is the difference
in the average outcomes when treatment is set to z and the intermediate variable is set to
the value that would have occurred under treatment compared to if the intermediate variable
were set to the value that would have occurred under control.
Though the total effect is identifiable assuming (2.20), the natural direct and indirect
effects are not identifiable since they entail E[Y (z, S(1 − z))] which depends on unobserved
counterfactual distributions. Sjo¨lander (2009) derived bounds for the natural direct effects
assuming only independent treatment assignment (2.20) using the linear programming tech-
nique of Balke and Pearl (1997). This results in the following sharp lower and upper bounds
for NDE0 and NDE1
max

−p11·0 − p10·0,
p11·1 + p01·0 − 1− p10·0,
p10·1 + p00·0 − 1− p11·0
 ≤ NDE0 ≤ min

p01·0 + p00·0,
1− p00·1 + p01·0 − p10·0,
1− p01·1 + p00·0 − p11·0
 (2.30)
max

−p01·1 − p00·1,
p00·0 − 1− p01·1 + p10·1,
p01·0 − 1− p00·1 + p11·1
 ≤ NDE1 ≤ min

p11·1 + p10·1,
1− p01·1 + p10·1 − p11·0,
1− p00·1 + p11·1 − p10·0
 (2.31)
where pys·z = Pr(Y = y, S = s|Z = z). These bounds may exclude 0, indicating a natural
direct effect of treatment z when the intermediate variable is set to S(z) (ignoring sampling
variability). There are instances where the bounds in (2.30) and (2.31) may collapse to a single
point, e.g., if p10·0 = p10·1 = 1. Using (2.29), bounds for NIE0 and NIE1 can be obtained by
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subtracting the bounds for NDE1 and NDE0 from the total effect, which is identified under
(2.20) and equal to (p11·1 + p10·1)− (p10·0 − p11·0).
Just as in Sections 2.2–2.4, monotonicity assumptions can be made to tighten the above
bounds. For instance, if
Pr[S(0) ≤ S(1)] = 1
Pr[Y (0, s) ≤ Y (1, s)] = 1 for s = 0, 1 and
Pr[Y (z, 0) ≤ Y (z, 1)] = 1 for z = 0, 1,
are assumed, then Pr[L = l] = 0 for all l such that (i) S(0) = 1 and S(1) = 0, (ii) Y (0, s) = 1
and Y (1, s) = 0 for s = 0 or 1, or (iii) Y (z, 0) = 1 and Y (z, 1) = 0 for s = 0 or 1, which
restricts the feasible region of the linear programming problem. The resulting sharp bounds
for the natural direct effect are
max
 0, p01·0 − p01·1, p10·1 − p10·0,p01·0 − p01·1 + p10·1 − p10·0
 ≤ NDEz ≤ p10·1 + p11·1 − p10·0 − p11·0 (2.32)
(Sjo¨lander, 2009). The bounds (2.32) are always at least as narrow as (2.30) and (2.31).
Interestingly these narrower bounds do not depend on z. The bounds in (2.32) may also
collapse to a single point, e.g., if p10·0 = p10·1 and p01·0 − p01·1 = p11·1 − p11·0.
The natural direct effect provides insight into whether or not treatment yields additional
benefit on the outcome of interest when the influence of treatment on the intermediate variable
is eliminated. However, researchers might also be interested in what benefit is provided by
treatment if the effect of the intermediate variable on the outcome is eliminated or held
constant. This question suggests a different causal estimand known as the controlled direct
effect. Bounds for the controlled direct effect can be found in Pearl (2001); Cai et al. (2008);
Sjo¨lander (2009); and VanderWeele (2011).
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2.5.2 Sensitivity Analysis
As in other settings where the effect of interest is not identifiable, sensitivity analysis in
the mediation setting may be conducted by making untestable assumptions that identify the
direct or indirect effects. Then sensitivity of inference to departures from these assumptions
can be examined. For example, if (2.20) holds, then the natural direct and indirect effects
are identified under the following additional assumptions
Y (z, s)qS|Z for z, s = 0, 1 and (2.33)
Y (z, s)qS(z′) for z, z′, s = 0, 1 (2.34)
(Pearl, 2001; VanderWeele, 2010). Assumption (2.33) would be valid if subjects were randomly
assigned S within different levels of treatment assignment Z. In settings where S is not
randomly assigned, (2.33) might be considered plausible if it is believed that conditional on Z
there are no variables which confound the mediator–outcome relationship. Both assumptions
(2.33) and (2.34) will not hold in general if Z has an effect on some other intermediate variable,
say R, which in turn has an effect on both S and Y . Thus (2.33) and (2.34) may fail unless the
mediator S occurs shortly after treatment Z. Under assumptions (2.20), (2.33) and (2.34),
NDEz = (−1)z
∑
s
{E[Y |Z = 1− z, S = s]− E[Y |Z = z, S = s]}Pr[S = s|Z = z]
and
NIEz = (−1)z
∑
s
E[Y |Z = z, S = s]{Pr[S = s|Z = 1− z]− Pr[S = s|Z = z]}.
Because assumptions (2.33) and (2.34) cannot be empirically tested, sensitivity analysis
should be conducted. Similar to Section 2.2.4, sensitivity analysis might proceed by positing
the existence of an unmeasured confounding variable U associated with the potential mediator
values S(z) and the potential outcomes Y (z, s) for z, s = 0, 1. Assumption (2.33) would then
replaced by Y (z, s) q S|{Z,U} and (2.34) by Y (z, s) q S(z′)|U for s, z, z′ = 0, 1. Sensitivity
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analysis would then proceed by exploring how inference about the natural direct and indirect
effects changes as the magnitude of the associations of U with S(z) and Y (s, z′) for z, z′, s =
0, 1 vary. For further details regarding bounds and sensitivity analysis in mediation analysis
see Imai et al. (2010); VanderWeele (2010); and Hafeman (2011).
2.6 Longitudinal Treatment
2.6.1 Background
In Sections 2.2–2.5 treatment is assumed to remain fixed across follow up time and out-
comes are one dimensional. However, frequently researchers are interested in assessing causal
effects comparing longitudinal outcomes for patients on different treatment regimens where
treatment may vary in time. As the number of times at which an individual may receive
treatment increases, the number of possible treatment regimens increases exponentially. Be-
cause each treatment regimen corresponds to a separate potential (longitudinal) outcome and
only one potential outcome is ever observed, the fraction of potential outcomes that are unob-
served quickly grows close to one as the number of possible treatment times increases. As in
other settings, unless treatment regimens are randomly assigned, regimen effects will not be
identifiable without additional assumptions. In the longitudinal setting bounds will typically
be largely uninformative because of the large proportion of unobserved potential outcomes.
Therefore analyses usually proceed by invoking modeling assumptions that render treatment
effects identifiable and then conducting sensitivity analysis corresponding to key untestable
modeling assumptions.
Models for potential outcomes as functions of covariates (such as treatment) and possibly
other potential outcomes are often referred to as structural models. For longitudinal poten-
tial outcomes and treatments, popular models include structural nested models and marginal
structural models (Robins et al., 1999; Robins, 1999; van der Laan and Robins, 2003; Brum-
back et al., 2004). In Section 2.6.2 below we consider a marginal structural model where
the treatment effect is identified assuming conditionally independent treatment assignment.
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Sensitivity analyses exploring departures from this assumption are then considered in Section
2.6.3.
2.6.2 Marginal Structural Model
Consider a study where individuals possibly receive treatment at τ fixed time points (i.e.,
study visits). In general let A¯(t) = (A(0), . . . , A(t)) represent the history of variable A up to
time t and A¯ be the entire history of variable A such that A¯ = A¯(τ). Let z(t) = 1 indicate
treatment at visit t, and z(t) = 0 otherwise such that z¯ represents a treatment regimen for
visits 0, . . . , τ . Denote the observed treatment regimen up to time t as Z¯(t). Let Y be some
outcome of interest that may be categorical or continuous, and denote the potential outcome
of Y at visit t for regimen z¯ by Y (z¯, t) and the observed outcome by Y (t). Let X¯(t) denote the
history of some set of time varying covariates up to time t, where X(0) denotes the baseline
covariates. Assume for simplicity there is no loss to follow-up or non-compliance such that
we observe n iid copies of (Z¯, Y¯ , X¯).
Consider the following marginal structural model of the mean potential outcome were the
entire population to follow regimen z¯ up to time t
g(E[Y (z¯, t)|X(0) = x(0)]) = β0 + β1cum[z¯(t− 1)] + β2t+ β3x(0) (2.35)
for t ∈ {1, . . . , τ}, where cum[z¯(t− 1)] = ∑t−1k=1 z(k) and g(·) is an appropriate link function.
The causal estimand of interest is β1, the regression coefficient for cum[z¯(t − 1)], which is
the effect of having received treatment at one additional visit prior to time t conditional on
baseline covariates X(0). Because (2.35) involves counterfactual outcome distributions, β1 is
not identifiable without additional assumptions. One additional assumption is conditionally
independent treatment assignment
Y (z¯, t)q Z(k)|{Z¯(k − 1), X¯(k)} for all z¯ and t > k (2.36)
(Robins et al., 1999; Robins, 1999; Brumback et al., 2004). This assumption is true if the
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potential outcome at visit t under treatment regimen z¯ is independent of the observed treat-
ment at visit k given the history of treatment up to visit k − 1 and the covariate history up
to visit k. Assuming both a correctly specified model (2.35) and conditionally independent
treatment assignment (2.36), fitting the following model to the observed data
g(E[Y (t)|Z¯(t− 1) = z¯(t− 1), X(0) = x(0)]) = η0 + η1cum[z¯(t− 1)] + η2t+ η3x(0),
using generalized estimating equations with an independent working correlation matrix and
time varying inverse probability of treatment weights (IPTW) yields an estimator ηˆ1 that is
consistent for β1 (Tchetgen Tchetgen et al., 2012a,b).
2.6.3 Sensitivity Analysis
If assumption (2.36) does not hold, then the IPTW estimator ηˆ1 is not necessarily con-
sistent. Because (2.36) is not testable from the observed data, sensitivity analysis might
be considered to assess robustness of inference to departures from (2.36). Following Robins
(1999) and Brumback et al. (2004), let
c(t, k, z¯(t− 1), x¯(k)) = E[Y (z¯, t)|Z¯(k) = z¯(k), X¯(k) = x¯(k)]−
E[Y (z¯, t)|Z(k) = 1− z(k), Z¯(k − 1) = z¯(k − 1), X¯(k) = x¯(k)]
for t > k and z¯ such that Pr[Z(k) = z(k)|Z¯(k− 1) = z¯(k− 1)] is bounded away from 0 and 1.
The function c quantifies departures from the conditional independent treatment assignment
assumption (2.36) at each visit t > k, where c(t, k, z¯(t − 1), x¯(k)) = 0 for all z¯ and t > k if
(2.36) holds. For the identity link, a bias adjusted estimator of the causal effect β1 may be
obtained by recalculating the IPTW estimator with the observed outcome Y (t) replaced by
Y γ(t) = Y (t)− b(Z¯(t− 1), X¯(t− 1)) where
b(Z¯(t− 1), X¯(t− 1)) =
t−1∑
k=0
c(t, k, Z¯(t− 1), X¯(k))f [1− Z(k)|Z¯(k − 1), X¯(k)]
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and f [z(k)|z¯(k−1), x¯(k)] = Pˆr[Z(k) = z(k)|Z¯(k−1) = z¯(k−1), X¯(k) = x¯(k)] is an estimate of
the conditional probability of the observed treatment based on some fitted parametric model
(Brumback et al., 2004). Provided this parametric model and c are both correctly specified,
this bias adjusted estimator, say η˜1, is consistent for β1. Sensitivity analysis proceeds by
examining how η˜1 changes when varying sensitivity parameters in c(t, k, z¯(t− 1), x¯(k)).
Because c(t, k, z¯(t − 1), x¯(k)) is not identifiable from the observable data, Robins (1999)
recommends choosing a particular c that is easily explainable to subject matter experts to
facilitate eliciting plausible ranges of the sensitivity parameters. As an example of a particular
c, Brumback et al. (2004) suggest c(t, k, z¯(t− 1), x¯(k)) = γ{2z(k)− 1} where γ is an uniden-
tifiable sensitivity analysis parameter. Note that c(t, k, z¯(t − 1), x¯(k)) = γ for z(k) = 1 and
c(t, k, z¯(t−1), x¯(k)) = −γ for z(k) = 0. Thus γ > 0 (γ < 0) corresponds to subjects receiving
treatment at time k having greater (smaller) mean potential outcomes at future visit t than
those who did not receive treatment at visit k. When γ = 0, Y (t) = Y γ(t) and therefore
η˜1 = ηˆ1. The function c might depend on the baseline covariates X(0) or the time-varying
covariates X¯(k). In this case, as in Section 2.2.5, care should be taken in clearly communicat-
ing the sensitivity parameters’ relationship to these covariates when eliciting plausible ranges
from subject matter experts. Another consideration when choosing a function c is whether it
will allow for the sharp null of no treatment effect, i.e., for all individuals Y (z¯, t) = Y (z¯′, t) for
all z¯, z¯′, t. The example function c presented above allows for the sharp null. See Brumback
et al. (2004) for other example c functions and further discussion of sensitivity analysis for
marginal structural models.
2.7 Ignorance and Uncertainty Regions
Treatment effect bounds describe ignorance due to partial identifiability but do not ac-
count for uncertainty due to sampling error. This section discusses some methods to appropri-
ately quantify uncertainty due to sampling variability when drawing inference about partially
identifiable treatment effects. Over the past decade a growing body of research, especially
in econometrics, has considered inference of partially identifiable parameters. The approach
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presented below draws largely upon Vansteelandt et al. (2006), who considered methods for
quantifying uncertainty in the general setting where missing data causes partial identifiability.
As questions about treatment (or causal) effects can be viewed as missing data problems, the
approach of Vansteelandt et al. generally applies (under certain assumptions) to the type of
problems considered throughout this paper. This approach builds on earlier work by Robins
(1997) and others.
2.7.1 Ignorance Regions
Let L be a vector containing the potential outcomes for an individual, let O denote the
observed data vector, and letR be a vector containing indicator variables denoting whether the
corresponding component of L is observed. For example, L = (Y (1), Y (0)), O = (Z, Y ), and
R = (Z, (1 − Z)) for the scenario described in Section 2.2 and L = (Y (1), Y (0), S(1), S(0)),
O = (Z, Y, S) and R = (Z, (1 − Z), Z, (1 − Z)) for the scenario described in Section 2.3.
Denote the distribution of (L,R) by f(L,R) and let f(L) =
∫
f(L,R)dR. The goal is to draw
inference about a parameter vector β which is a functional of the distribution of potential
outcomes L; this is sometimes made explicit by writing β = β{f(L)}. Denote the true
distribution of (L,R) by f0(L,R) and the true value of β by β0 = β{f0(L)}. For example,
β0 = E[Y (1)−Y (0)] for the scenario described in Section 2.2 and β0 = E[Y (1)−Y (0)|SP0 =
(1, 1)] for the scenario described in Section 2.3. Denote the true observed data distribution by
f0(O) =
∫
f0(L,R)dL(1−R) where L(1−r) denotes the missing part of L when R = r (i.e., the
unobserved potential outcomes). The challenge in drawing inference about β0 is that there
may be multiple full data distributions f(L,R) that marginalize to the true observed data
distribution, i.e., f0(O) =
∫
f(L,R)dL(1−R) for some f 6= f0. When this occurs, β may be
only partially identifiable from O, in which case bounds can be derived for β0 as illustrated
in the sections above.
The set of values of β{f(L)} such that f(L,R) marginalizes to the true observed data
distribution is sometimes called the ignorance region or the identified set. These ignorance
regions or intervals are distinct from traditional confidence intervals in that even as the sample
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size tends to infinity these intervals will not shrink to a single point when β is partially
identifiable. The ignorance region for β can be defined formally as follows. Following Robins
(1997), define a class M(γ) of full data laws indexed by some sensitivity parameter vector γ
to be non-parametrically identified if for each observed data law f(O) there exists a unique
law f(L,R; γ) ∈M(γ) such that f(O) = ∫ f(L,R; γ)dL(1−R). In other words, the class M(γ)
contains a unique distribution that marginalizes to each possible observed data distribution.
For example, for the sensitivity analysis approach in Section 2.3.4, Hudgens and Halloran
(2006, §4.3.3) defined a class of full data laws indexed by γ given in (2.19) that is non-
parametrically identified. The ignorance region for β is formally defined to be
irf0(β,Γ) =
{
β{f(L)} : f(L) =
∫
f(L,R; γ)dR for some
f(L,R) ∈M(Γ) such that
∫
f(L,R; γ)dL(1−R) = f0(O)
}
, (2.37)
where Γ is the set of all possible values of γ under whatever set of assumptions is being
invoked and M(Γ) = ∪γ∈ΓM(γ). Assume M(Γ) contains the true full data distribution, i.e.,
f0(L,R) = f(L,R, γ0) for some γ0 ∈ Γ. (For considerations when M(Γ) does not contain
the true full data distribution, see Todem et al. (2010).) Because M(γ) is non-parametrically
identified, for each γ ∈ Γ there is a single β(γ) = β{∫ f(L,R; γ)dR)} in the ignorance region
(2.37). If M(Γ) includes all possible full data distributions that marginalize to any possible
observed data distribution, then the ignorance region will contain the bounds.
In practice the ignorance region will be unknown because it depends on the unknown
true observed data distribution f0(O). For γ fixed, β(γ) is identifiable from the observed
data and the ignorance region can be estimated by estimating β(γ) for each value of γ ∈ Γ,
denoted by βˆ(γ). The resulting estimator of irf0(β,Γ) is then {βˆ(γ) : γ ∈ Γ}. For scalar β(γ),
let βˆl = infγ∈Γ{βˆ(γ)} and βˆu = supγ∈Γ{βˆ(γ)} such that the estimated ignorance region is
contained in the interval [βˆl, βˆu].
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2.7.2 Uncertainty Regions
Estimated ignorance regions convey ignorance due to partial identifiability and do not
reflect sampling variability in the estimates. Indeed much of the literature on bounds and
sensitivity analysis of treatment effects tends to report estimated ignorance regions and either
ignores sampling variability or employs ad-hoc inferential approaches such as pointwise con-
fidence intervals conditional on each value of the unidentifiable sensitivity parameter. More
recent developments have provided a formal framework for conducting inference in partial
identifiability settings (e.g., see Imbens and Manski, 2004; Vansteelandt et al., 2006; Romano
and Shaikh, 2008; Bugni, 2010; Todem et al., 2010). The main focus in this research has been
the construction of confidence regions for either the parameter β0 or the ignorance region
irf0(β0,Γ).
Following Vansteelandt et al. (2006), a (1 − α) pointwise uncertainty region for β0 is
defined to be a region URp(β,Γ) such that
inf
γ∈Γ
Prf0 {β(γ) ∈ URp(β,Γ)} ≥ 1− α,
where Prf0 {·} denotes probability under f0(O). That is, URp(β,Γ) contains β(γ) with at
least probability 1 − α for all γ ∈ Γ. In particular, assuming γ0 ∈ Γ, then URp(β,Γ) will
contain β0 = β(γ0) with at least probability 1− α.
An appealing aspect of pointwise uncertainty regions is that they retain the usual duality
between confidence intervals and hypothesis testing. Namely, one can test the null hypothesis
H0 : β0 = βc versus Ha : β0 6= βc for some specific βc at the α significance level by rejecting
H0 when the (1−α) pointwise uncertainty region URp(β,Γ) excludes βc. This is easily shown
by noting for βc = β(γ0)
Prf0 [reject H0] = 1− Prf0 {β(γ0) ∈ URp(β,Γ)}
≤ 1− infγ∈ΓPrf0 {β(γ) ∈ URp(β,Γ)} ≤ α,
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where the last inequality follows because URp(β,Γ) is a (1−α) pointwise uncertainty region.
Various methods under different assumptions have been proposed for constructing point-
wise uncertainty regions. Imbens and Manski (2004) and Vansteelandt et al. (2006) proposed
a simple method for constructing pointwise uncertainty regions for a scalar β with ignorance
region [βl, βu]. Let γl, γu ∈ Γ be the values of the sensitivity parameter such that βl = β(γl)
and βu = β(γu). Assume
There exist βˆl such that
√
n(βˆl − βl)→d N(0, σ2l ) and βˆu such that
√
n(βˆu − βu)→d N(0, σ2u).
(2.38)
The values γl and γu are the same for all possible observed data laws. (2.39)
Under assumptions (2.38) and (2.39) an asymptotic (1−α) pointwise uncertainty interval for
β0 is
URp(β,Γ) =
[
βˆl − cασ̂l/
√
n, βˆu + cασ̂u/
√
n
]
, (2.40)
where cα satisfies
Φ
cα +
√
n
(
βˆu − βˆl
)
max{σ̂l, σ̂u}
− Φ(−cα) = 1− α, (2.41)
Φ(·) denotes the cumulative distribution function of a standard normal variate, and σ̂l and σ̂u
are consistent estimators of σl and σu respectively (Imbens and Manski, 2004; Vansteelandt
et al., 2006). Note if βˆu−βˆl > 0 and n is large such that the left side of (2.41) is approximately
equal to 1−Φ(−cα), then cα ≈ z1−α, the (1− α) quantile of a standard normal distribution.
In contrast, if βˆu = βˆl, then cα = z1−α/2.
In addition to the pointwise uncertainty region, Horowitz and Manski (2000) and Vanstee-
landt et al. (2006) define a (1− α) strong uncertainty region for β0 to be a region URs(β,Γ)
such that
Prf0 {irf0(β,Γ) ⊆ URs(β,Γ)} ≥ 1− α,
i.e., URs(β,Γ) contains the entire ignorance region with probability at least 1−α. Whereas the
pointwise uncertainty region can be viewed as a confidence region for the partially identifiable
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target parameter β0, the strong uncertainty region is a confidence region for the ignorance
region irf0(β,Γ). Clearly any strong uncertainty region will also be a (conservative) pointwise
uncertainty region as β0 ∈ irf0(β,Γ). Under assumptions (2.38) and (2.39) an asymptotic
(1− α) strong uncertainty interval for scalar β0 is simply
URs(β,Γ) =
[
βˆl − z1−α/2σ̂l/
√
n, βˆu + z1−α/2σ̂u/
√
n
]
. (2.42)
Note that (2.42) is equivalent to the union of all pointwise (1−α) confidence intervals for β(γ)
under M(γ) over all γ ∈ Γ, which is a simple approach often employed when reporting sensi-
tivity analysis. Because strong uncertainty intervals are necessarily pointwise intervals, this
simple approach is also a valid method for computing pointwise intervals, although intervals
based on (2.40) will always be as or more narrow.
The two key assumptions (2.38) and (2.39) may not hold in general. For example, (2.38)
may not hold for all possible observed data distributions, particularly for extreme values of γl
or γu. Assumption (2.39) may not hold if different observed data distributions place different
constraints on the possible range of γ or if Γ is chosen by the data analyst on the basis of the
observed data. If (2.38) or (2.39) does not hold, alternative inferential methods are needed
(e.g., see Vansteelandt and Goetghebeur, 2001; Horowitz and Manski, 2006; Chernozhukov
et al., 2007; Romano and Shaikh, 2008; Stoye, 2009; Todem et al., 2010; Bugni, 2010).
A third approach to quantifying uncertainty due to sampling variability is to consider β(·)
as function of γ and construct a (1− α) simultaneous confidence band for the function β(·).
That is, a random function CB(·) is found such that
Prf0 {β(γ) ∈ CB(γ) for all γ ∈ Γ} ≥ 1− α.
It follows immediately that ∪γ∈ΓCB(γ) is a strong uncertainty region (and thus a pointwise
uncertainty region as well). Todem et al. (2010) suggest a bootstrap approach to constructing
confidence bands.
Whether pointwise uncertainty regions, strong uncertainty regions, or confidence bands
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are preferred will be context specific. Typically it is of interest to draw inference about a single
target parameter and not the entire ignorance region. Thus, in general pointwise uncertainty
regions may have greater utility than strong uncertainty regions. Because strong uncertainty
regions are necessarily conservative pointwise uncertainty regions, the strong regions can be
useful in settings where determining a pointwise region is more difficult. Additionally, in
some settings it may be of interest to assess whether β is non-zero, e.g., if β denotes the
effect of treatment. In these settings computing a confidence band CB(·) has the advantage
of providing the subset of Γ where the null hypothesis β(γ) = 0 can be rejected. This is
especially appealing if γ is scalar, in which case a confidence band (as in Figure 3 of Todem
et al., 2010) provides a simple approach to reporting sensitivity analysis results. On the
other hand, if γ is multidimensional, visualizing confidence bands can be difficult and instead
reporting the (pointwise or strong) uncertainty region may be more practical.
2.7.3 Data Example
Returning to the pertussis vaccine study described in Section 2.3, an analysis that ignores
the potential for selection bias might entail computing a naive estimator (the difference in
empirical means of Y between the vaccinated and unvaccinated amongst those infected) along
with a 95% Wald confidence interval, which would be -0.31 (95% CI -0.38, -0.23). If the
sensitivity analysis approach in Section 2.3.4 is applied, the parameter of interest β(γ) =
E[Y (1)− Y (0)|SP0 = (1, 1)] is identified for fixed values of the sensitivity analysis parameter
γ given in (2.19). For fixed γ, E[Y (0)|SP0 = (1, 1)] equals the intersection of the negative
sloped line (2.14) and the curve (2.19), which is illustrated in Figure 2.1 for the pertussis data.
Because E[Y (0)|SP0 = (1, 1)] increases with γ, β(γ) is a monotonically decreasing function of
γ. Therefore γl and γu equal the maximum and minimum values of Γ regardless of the observed
data law, indicating (2.39) holds provided that Γ is chosen by the analyst independent of the
observed data.. For γ fixed and finite, β(γ) can be estimated via nonparametric maximum
likelihood (i.e., without any additional assumptions). This estimator will be consistent and
asymptotically normal under standard regularity conditions if Pr[S(0) > S(1)] > 0 (i.e., the
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Table 2.1: Pertussis vaccine study data: Estimated ignorance regions and 95% pointwise and
strong uncertainty regions of β = E[Y (1)− Y (0)|SP0 = (1, 1)] for different Γ.
Γ irf0(β,Γ) URp(β,Γ) URs(β,Γ)
[−3, 3] [-0.49, -0.17] [-0.58, -0.07] [-0.59, -0.06]
[−5, 5] [-0.55, -0.15] [-0.66, -0.05] [-0.69, -0.03]
[−10, 10] [-0.57, -0.15] [-0.70, -0.04] [-0.73, -0.02]
(−∞,∞) [-0.57, -0.15] [-0.70, -0.04] [-0.73, -0.02]
vaccine has a protective effect against infection). For γ = ±∞ and Pr[S(0) > S(1)] > 0, Lee
(2009) proved that the estimators of the bounds similar to those given in Section 2.3.3 are
consistent and asymptotically normal for a continuous outcome Y . The limiting distribution
of the estimator of the upper bound (γ = −∞) for a binary outcome will be normal if in
addition
1− E[Y |S = 1, Z = 0] 6= Pr[S = 1|Z = 1]
Pr[S = 1|Z = 0] , (2.43)
and similarly the estimator of the lower bound (γ = ∞) will be asymptotically normal if in
addition
E[Y |S = 1, Z = 0] 6= Pr[S = 1|Z = 1]
Pr[S = 1|Z = 0] . (2.44)
Likelihood ratio tests for the null hypotheses that (2.43) and (2.44) do not hold yield p-values
p < 10−4 and p = 0.18 respectively, indicating strong evidence that (2.43) holds and equivocal
evidence regarding (2.44). Assuming (2.43) and (2.44) both hold implies (2.38), such that
(2.40) and (2.42) can be used to construct (1−α) pointwise and strong uncertainty intervals
for β0. Estimated ignorance and uncertainty intervals of β0 for different choices of Γ are
given in Table 2.1 and Figure 2.2, with standard error estimates obtained using the observed
information. Even for Γ = (−∞,∞) both the pointwise and strong uncertainty intervals
exclude zero, indicating a significant effect of vaccination. In particular, with 95% confidence
we can conclude the vaccine decreased the risk of severe disease among individuals who would
have become infected regardless of vaccination.
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2.8 Discussion
This paper considers conducting inference about the effect of a treatment (or exposure)
on an outcome of interest. Unless treatment is randomly assigned and there is perfect com-
pliance, the effect of treatment may be only partially identifiable from the observable data.
Through the five settings in Sections 2.2 – 2.6, we discussed two approaches often employed to
address partial identifiability: (i) bounding the treatment effect under minimal assumptions,
or (ii) invoking additional untestable assumptions that render the treatment effect identifiable
and then conducting sensitivity analysis to assess how inference about the treatment effect
changes as the untestable assumptions are varied. Incorporating uncertainty due to sampling
variability was discussed in Section 2.7, and throughout large-sample frequentist methods
were considered. Analogous Bayesian approaches to partial identification (Gustafson, 2010;
Moon and Schorfheide, 2012; Richardson et al., 2011) and sensitivity analysis (McCandless
et al., 2007; Gustafson et al., 2010) have also been developed.
Determining treatment effect bounds is essentially a constrained optimization problem,
where the constraints are determined by the relationship between the distributions of the
observable random variables and of the potential outcomes under whichever assumptions are
being made. In simple cases, such as in Section 2.2.1, bounds can easily be derived from first
principles and may have simple closed forms; in more complicated settings, such as in Section
2.4, bounds may be determined using linear programming or other optimization methods.
In many cases calculating bounds under minimal assumptions may seem to be a meaningless
exercise because the bounds are often quite wide and may not exclude the null of no treatment
effect as seen with the “no assumptions” bounds in Section 2.2. On the contrary, in settings
like this Robins and Greenland (1996) write: “Some argue against reporting bounds for
nonidentifiable parameters, because bounds are often so wide as to be useless for making
public health decisions. But we view the latter problem as a reason for reporting bounds in
conjunction with other analyses: Wide bounds make clear that the degree to which public
health decisions are dependent on merging the data with strong prior beliefs.”
Bounds may be narrowed by reducing the feasible region of the optimization problem. This
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may be accomplished by considering further assumptions that place restrictions on either the
distributions of the potential outcomes, the distributions of the observable random variables,
or both. Assumptions that place restrictions on the observable random variables may have
implications which are testable. If the observed data provide evidence against any assumptions
being considered, bounds should be computed without making these assumptions. Those
assumptions without testable implications can only be determined to be plausible or not by
subject matter experts.
A potentially less conservative approach to computing bounds is to make untestable as-
sumptions which identify the causal estimand and then assess the robustness of inference
drawn to departures from these assumptions in a sensitivity analysis. A general guideline
for specifying the sensitivity analysis parameters representing these departures is to choose
parameters that are easily interpretable to subject matter experts. Parameter specification
will depend on whether or not sensitivity analysis is conducted by directly modeling the asso-
ciation of an unmeasured confounder U with treatment selection and the potential outcomes.
Sensitivity analyses based on this approach are applicable when the existence of U is known
and there is some historical knowledge of the magnitude association of U with Z and the
potential outcomes (Robins, 1999; Brumback et al., 2004). Otherwise, alternative approaches
based on directly modeling the unobserved potential outcome distributions may be preferred.
A second guiding principle should be to avoid specifications of sensitivity parameters that
place restrictions on the distributions of observable random variables that are not empirically
supported. A third consideration when conducting sensitivity analysis concerns determining
a plausible region of the sensitivity parameters. That the region be chosen prior to data
analysis is in general necessary for inference, such as described in Section 2.7, to be valid.
Choice of the region of the sensitivity parameters may be dictated by whether one wants to
consider only mild or also severe departures from the identifying assumptions. If the identify-
ing assumption in question is considered plausible, then it may be that only mild departures
from the assumption are deemed necessary for the sensitivity analysis. In this case, subject
matter experts can be consulted to determine, prior to data analysis, a plausible region for the
sensitivity parameters. If, on the other hand, severe departures from untestable identifying
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assumptions are to be entertained, sensitivity analyses should be conducted over all possible
values of the sensitivity parameters. Sensitivity analyses which consider all possible full data
distributions that marginalize to the observed data distribution will yield ignorance regions
containing the bounds.
Though the examples presented here demonstrate the broad scope of scenarios where
bounds and sensitivity analysis methods have been derived and employed to draw inference
about treatment effects, they certainly are not exhaustive of all settings where these methods
have been developed. For instance, VanderWeele et al. (2011) consider sensitivity analysis
to unmeasured confounding for causal interaction effects. Bounds and sensitivity analysis
methods have also recently been considered in the presence of interference, i.e., in settings
where treatment of one individual may affect the outcome of another individual, such as
in social networks (Ver Steeg and Galstyan, 2010; Vanderweele, 2011; Manski, 2013). For
studies where sensitivity analyses are planned or anticipated, Rosenbaum and colleagues have
examined how aspects of study design and the choice of statistical tests or estimators may
affect the power or precision of the sensitivity analyses to be conducted (Heller et al., 2009;
Rosenbaum, 2010a,b, 2011).
Bounds and sensitivity analyses of treatment effects have been utilized in various substan-
tive settings, such as biomedical research (e.g., Cole et al., 2005; Rerks-Ngarm et al., 2009;
VanderWeele and Herna´ndez-Diaz, 2011; Hu et al., 2012) and economics (e.g., Heckman, 2001;
Sianesi, 2004; Armstrong et al., 2010). Nonetheless, despite the wide range of settings in which
these methods are applicable, their use in substantive settings remains somewhat limited in
frequency. Given the large amount of literature detailing their broad scope of applicability
and that formal inferential methods for partially identifiable parameters are now available,
hopefully these approaches will be employed with greater frequency in substantive settings in
the future.
The sensitivity analyses described throughout this paper focus on departures from untestable
assumptions which identify treatment effects. Other types of sensitivity analyses might be
considered as well, e.g., to assess how robust inferences are to various analytical decisions
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that are invariably made in data analysis. Rosenbaum (2002, §11.9) refers to such assess-
ment as “stability analysis,” in contrast to the types of sensitivity analyses discussed above.
See Rosenbaum (1999, 2002) and Morgan and Winship (2007, §6.2) for further discussion
regarding various types of sensitivity analyses beyond the type considered here.
Figure 2.1: Graphical depiction of the bounds and sensitivity analysis model described in
Sections 2.3.3 – 2.3.4. The solid thin line with negative slope represents a set of joint dis-
tribution functions of (Z, S(1), S(0), Y (1), Y (0)) that all give rise to the same distribution
of the observable random variables (Z, S, Y ). The four dotted curves depict the log odds
ratio selection model for γ = 0, 1, 2, 4. The γ = 0 model is equivalent to the no selection
model. Each selection model identifies exactly one pair of expectations from this set, render-
ing the principal effect (2.10) identifiable. The thick black lines on the edge of the unit square
correspond to the lower bound of the principal effect.
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Figure 2.2: Estimated ignorance regions irf0(β,Γ) and 95% pointwise uncertainty regions
URp(β,Γ) for the pertussis vaccine example in Section 2.7.3. The principal effect (2.10) is
denoted β and Γ = [−γu, γu] for γu along the horizontal axis. The curve given by the lower
boundary of the area with black slanted lines corresponds to βˆl, the minimum of the estimated
ignorance regions, and the upper bound of the area with black slanted lines corresponds to βˆu,
the maximum of the estimated ignorance region. The curve given by the lower (upper) bound-
ary of the gray shaded area corresponds to the minimum (maximum) of the 95% pointwise
uncertainty region.
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CHAPTER 3: NONPARAMETRIC INSTRUMENTAL VARIABLE
ANALYSIS OF COMPETING RISKS DATA
3.1 Introduction
In both randomized and non-randomized studies, researchers may seek to assess the causal
effect of a treatment on the time to some event of interest, such as the effect of infant or ma-
ternal antiretroviral (ARV) therapy on the time to death or HIV infection of a breastfeeding
infant of an HIV+ woman. However, such treatment effects are not identifiable without mak-
ing empirically untestable assumptions about the relationship between the various causes of
the event, the time to the event and the treatment allocation mechanism. With the exception
of randomized clinical trials with perfect compliance to treatment assignment, the treatment
allocation mechanism is unknown, which may confound standard “as treated” analyses. Such
unmeasured confounding may bias treatment effect estimates in both observational studies
and randomized studies with non-compliance to assigned treatment.
In some circumstances there may exist variables that are not related to the outcome ex-
cept through their effect on treatment allocation. Such variables may be used to provide
partial or point identification of treatment effects without knowledge of the treatment al-
location mechanism (Manski, 1990; Imbens and Angrist, 1994; Angrist et al., 1996). These
variables are referred to as instrumental variables and examples include treatment assignment
in randomized clinical trials with non-compliance (Imbens and Angrist, 1994; Angrist et al.,
1996), the calendar time for the approval of a new treatment by a regulatory agency (Martens
et al., 2006; Cain et al., 2009), physician treatment prescribing preference (Brookhart and
Schneeweiss, 2007), or randomized encouragement to take treatment (Martens et al., 2006). If
the effect of the instrumental variable on treatment allocation is monotonic, then the instru-
mental variable may be used to identify treatment effects within the subpopulation whose
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treatment is determined by the instrumental variable (Imbens and Angrist, 1994; Angrist
et al., 1996; Herna´n and Robins, 2006).
Instrumental variables have been used to identify treatment effects describing differences
in survival analysis functions between treatment arms within the subpopulation described
above. Inferential methods for censored data have been developed using both nonparametric
methods (Baker and Lindeman, 1994; Baker, 1998; Abbring and van den Berg, 2005; Nie
et al., 2011) as well as parameteric and semiparametric modelling techniques (Robins and
Tsiatis, 1991; Loeys and Goetghebeur, 2003; Cuzick et al., 2007). In this paper, we consider
competing risks data with multiple failure types and decompose the overall causal effect of
treatment on the survival probability at a fixed time point into the sum of its causal effects
on the various cause specific subdistributions. If an instrumental variable does not share
common causes with either the time to the event or type of event experienced, it may be
used to identify the cause-specific causal effect based on the difference in the cause-specific
cumulative incidence function between treatment arms. Inferences may be obtained using
nonparametric estimates of the cumulative incidence functions, analogously to the overall
causal effect estimator which may entail nonparametric estimators of the survival functions.
Typically, in survival analysis, one performs an intent to treat test for differences in
treatment specific survival functions using the log-rank statistic. This nonparametric test
provides a global assessment of differences in survival functions over time. To our knowledge,
the existing literature on nonparametric analyses of censored data with instrumental variables
does not address testing for global treatment differences, providing inferential methods only
at fixed time points (Baker and Lindeman, 1994; Baker, 1998; Abbring and van den Berg,
2005; Nie et al., 2011). In this paper we develop test statistics for differences in overall
survival which are integrated weighted differences of the estimated causal effects over time,
where the weight function may be chosen to emphasize time points of greatest interest. The
tests are easily implemented using a straightforward variance estimator and are theoretically
justified. The proposed statistics are extended to the competing risks setting, where they
are constructed from nonparametric estimators of the differences in the treatment specific
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cumulative incidence functions.
As an example of a setting where such methods may be applicable, consider the Breastfeed-
ing, Antiretrovirals, and Nutrition (BAN) randomized clinical trial undertaken in Lilongwe,
Malawi between 2004 and 2010 (Chasela et al., 2010). In this study 2369 HIV-infected breast-
feeding mothers and their uninfected newborn babies were randomly assigned to one of three
treatment regimens: maternal antiretrovial (ARV) therapy (n = 849); daily infant nevirap-
ine (NVP) therapy (n = 852); or control (n = 668). The aim was to assess the effect of
these treatment regimens on reducing mother to child transmission of HIV. Two challenges
in the analysis of data from such trials are (i) not all participants comply to their randomized
treatment regimen assignment and (ii) death (prior to HIV infection) is a competing risk
for HIV infection. The randomized treatment assignment provides an instrumental variable
that allows for estimation of treatment effects amongst those who would comply to whichever
treatment they were assigned. In the BAN study treatment regimen adherence was measured
via surveys administered to the mothers, allowing for estimation of such effects (assuming
accurate self-report).
The organization of the paper is as follows. In Section 3.2 notation, assumptions, causal
estimands and estimators are given, both for the overall and cause-specific causal effects.
Section 3.3 describes nonparametric inferences using the estimators for both the standard
survival set-up as well as in the presence of competing risks, and gives details of nonparametric
test statistics for a global assessment of the causal effects over time. Section 3.4 presents the
results of a simulation study examining the finite sample performance of these estimators and
tests. Section 3.5 applies the methods derived in Section 3.3 to the BAN study. Section 3.6
concludes with a discussion.
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3.2 Preliminaries
3.2.1 Notation
An instrumental variable that is often used to estimate causal effects is randomized treat-
ment assignment in a clinical trial. Let R be an instrumental variable given by randomized
assignment where R = 0 indicates assignment to control and R = 1 indicates assignment to
treatment (e.g. maternal or infant ARV therapy in the BAN study). Though treatment ef-
fects of R on the outcome of interest may be identifiable if R is randomly assigned, treatment
effects due to the actual treatment taken (which may differ from R) are typically the target
of inference. Let Z be the actual treatment taken, where Z = 0 denotes treatment not taken,
Z = 1 denotes that treatment was taken. Define potential treatment outcomes Z(r) under
randomized treatment assignment r = 0, 1; specifically let Z(r) = 0 indicate that the subject
would not take treatment under randomized assignment r and Z(r) = 1 indicates that the
subject would take treatment under randomized assignment r. As in Imbens and Angrist
(1994) and Angrist et al. (1996), define principal strata based on the vector of the treatment
potential outcomes ZP0 = (Z(0), Z(1)) where ZP0 = (0, 1) are compliers (i.e. they only take
treatment if they were assigned to do so), ZP0 = (1, 1) are the always treated, ZP0 = (0, 0)
are the never treated, and ZP0 = (1, 0) are defiers (i.e. they would only take treatment when
not assigned to do so).
Suppose we are interested in time to event outcomes that may be subject to competing
risks. Let T (r, z) be the potential first failure times under treatment assignment z and
randomized assignment r and ∆(r, z) the potential event type or cause indicators that may
take on values 1, . . . , J . Let T be the observed time to the first event for event types j =
1, . . . , J , C be the censoring time and X the minimum of T and C (which is the observed
follow up time). Let ∆ = jI[T ≤ C]) be the observed event indicator where ∆ = 0 indicates
that the subject was lost to follow up before the event was experienced. Suppose we observe
n i.i.d copies of {Xi, Ri, Zi,∆i}.
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3.2.2 Assumptions
Assumption 3.1. Stable unit treatment value assumption (Rubin, 1978, SUTVA): if R = r
and Z = z then Z(R) = Z(r) and T (R,Z) = T (r, z) and ∆(R,Z) = ∆(r, z) for r, z = 0, 1.
Assumption 3.2. Independent instrument: R q {T (r, z), Z(r) for r, z = 0, 1}.
Assumption 3.3. Exclusion restriction: T (0, z) = T (1, z) and ∆(0, z) = ∆(1, z) for z = 0, 1
Assumption 3.4. Nonzero causal effect of R on Z: E[Z(1)− Z(0)] 6= 0.
Assumption 3.5. Monotonicity (Imbens and Angrist, 1994): Z(1) ≥ Z(0).
Assumption 3.6. Independent censoring: {T,∆} q C|R.
Assumption 3.1 is a standard assumption made in order to estimate causal effects defined
using potential outcomes. Assumptions 3.2–3.4 qualify R as an instrumental variable and are
the same assumptions found in Imbens and Angrist (1994) and Angrist et al. (1996). When
the instrumental variable is randomly assigned, Assumption 3.2 will typically be considered
plausible. Assumption 3.3 means that the potential outcomes only depend on z such that
we may write T (z) = T (r, z) and ∆(z) = ∆(r, z). Assumption 3.5 implies that the defiers
principal strata ZP0 = (1, 0) is empty (i.e., there is no subject that would take treatment
only when not assigned to do so). Assumption 3.6 is made in order to estimate the all cause
survival function and subdistribution functions in presence of right censoring.
3.2.3 Causal estimands
We are interested in causal effects describing differences between the survival curves of
the treated versus the nontreated within the subpopulation defined by ZP0 = (0, 1). This is
sometimes referred to as a local average treatment effect and is defined as
δ(t) = Pr[T (1) > t|ZP0 = (0, 1)]− Pr[T (0) > t|ZP0 = (0, 1)]. (3.1)
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Under Assumptions 3.1–3.5, (3.1) is equivalent to
δ(t) =
Pr[T > t|R = 1]− Pr[T > t|R = 0]
Pr[Z = 1|R = 1]− Pr[Z = 1|R = 0] =
S1(t)− S0(t)
p1 − p0 =
dS(t)
dp
(3.2)
where Sr(t) = Pr[T > t|R = r] is the survival function given R = r and pr = Pr[Z = 1|R =
r]. In absence of right censoring, (3.2) is equivalent to the standard instrumental variables
estimand of Imbens and Angrist (1994) and Angrist et al. (1996). Under Assumptions 3.2
and 3.6, a consistent estimator δ̂(t) is found by plugging in the Kaplan Meier estimator of
the survival functions Ŝr(t) = P̂r[T > t|R = r] at time t and conditional on R = r as well as
a consistent estimator of each pr such as an empirical sample mean of Z given R = r (Baker,
1998; Abbring and van den Berg, 2005; Nie et al., 2011). This will be called the instrumental
variables (IV) estimator of δ(t).
The local average treatment effect maybe further broken down into cause specific local
average treatment effects describing differences in the subdistribution functions for specific
cause j when there are competing risks for the failure time T . Namely, a local average
treatment effect for cause j can defined as
δj(t) = Pr[T (0) ≤ t, ∆(0) = j|ZP0 = (0, 1)]− Pr[T (1) ≤ t,∆(1) = j|ZP0 = (0, 1)]. (3.3)
It follows that δ(t) =
∑J
j=1δ
j(t), i.e., the local average treatment effect can be decomposed
into the sum of cause-specific effects. Note the local average treatment effects can be zero
while some of the cause specific effects are nonzero, e.g., if there are
∑J
j 6=j′ δ
j′(t) = −δj(t)
then this would occur. In context of the BAN study this could occur if infant (or maternal)
ARV resulted in a reduced proportion of infants being infected with HIV, but also increased
the proportion of infants dying (perhaps due to drug side effects) such that the proportions
dying or becoming infected are the same in the treated versus the control arms.
In order to arrive at an expression of (3.3) that is identifiable from observable data,
Assumption 3.2 will be replaced by the stronger condition given below.
Assumption 3.7. Jointly independent instrument: R q {T (r, z), Z(r),∆(z) for r, z = 0, 1}.
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Under Assumptions 3.1–3.5 and 3.7, (3.3) is equivalent to the following
δj(t) =
Pr[T ≤ t, ∆ = j|R = 0]− Pr[T ≤ t, ∆ = j|R = 1]
Pr[Z = 1|R = 1]− Pr[Z = 1|R = 0] =
F j0 (t)− F j1 (t)
p1 − p0 =
dF j(t)
dp
(3.4)
where F jr (t) = Pr[T ≤ t, ∆ = j|R = r] is the subdistribution (or cumulative incidence)
function for cause j given R = r. Under Assumptions 3.6-3.7, a consistent estimator δ̂j(t) is
found by plugging in the Aalen and Johansen (1978) estimator of the subdistribution function
F̂ jr (t) = P̂r[T ≤ t, ∆ = j|R = r] for cause j at time t and conditional on R = r and consistent
estimates of each pr. This will be called the IV estimator of δ
j(t). As with the estimands in
(3.2) and (3.4), the estimator of the all cause local average treatment effect δ̂(t) equals the
sum of the estimators of the cause specific local average treatment effects
∑J
j=1δ̂
j(t).
3.3 Asymptotic Distributional Results
3.3.1 Pointwise Confidence Intervals
Here asymptotic pointwise confidence intervals for the local average treatment effect and
the cause specific local average treatment effect are derived for some t ∈ (0, τ) where τ is the
maximum follow up time. To present our estimation procedure, some additional notation is
needed. Define Y i(t) =I(Xi ≥ t) to be the unconditional at risk process, Y ir = I(Xi ≥ t, Ri =
r) the conditional at risk process for randomized assignment r, and Y irz = I(Xi ≥ t, Ri =
r, Zi = z) the conditional at risk process for randomized assignment r and treatment z. Define
N ji(t) = I(Xi < t,∆i = j) to be counting processes for the number of failures of type j up to
time t. Let N jir (t) = I(Xi < t,∆i = j, Ri = r) be the number of failures of type j up to time
t for randomized treatment assignment r, and let N jirz(t) = I(Xi < t,∆i = j, Ri = r, Zi = z)
be the number of failures of type j up to time t for randomized treatment assignment r
and treatment z. Let N i(t)=
∑J
j=1N
ji(t), N ir(t)=
∑J
j=1N
ji
r (t), N irz(t)=
∑J
j=1N
ji
rz(t) be the
corresponding total failures. Throughout, assume time is continuous such that N i(t) and
N i
′
(t) do not jump at the same time for any i 6= i′ = 1 . . . n. Let the all cause hazard function
be denoted by λ(t) = limdt→0 Pr[T ∈ (t, t+dt)|T > t]/dt. Similarly, let λr(t) = limdt→0 Pr[T ∈
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(t, t+ dt)|R = r, T > t]/dt and λrz(t) = limdt→0 Pr[T ∈ (t, t+ dt), Z = z| R = r, T > t]/dt.
Let the cause specific hazard functions be λj(t) = limdt→0 Pr[T ∈ (t, t+dt),∆ = j|T > t]/dt.
Similarly, let λjr(t) = limdt→0 Pr[T ∈ (t, t+ dt),∆ = j|R = r, T > t]/dt and λjrz(t) = limdt→0
Pr[T ∈ (t, t + dt),∆ = j, Z = z| R = r, T > t]/dt. Here we will consider the sequences of
counting processes N j(t) =
∑n
i=1N
ji(t), N(t) =
∑J
j=1N
j(t), N jr (t) =
∑n
i=1N
ji
r (t), Nr(t)
=
∑J
j=1N
j
r (t), N
j
rz(t) =
∑n
i=1N
ji
rz(t), Nrz(t) =
∑J
j=1N
j
rz(t), Y (t) =
∑n
i=1 Y
i(t), Yr(t) =∑n
i=1 Y
i
r (t) and Yrz(t) =
∑n
i=1 Y
i
rz(t). Let nr =
∑n
i=1 I[Ri = r].
Proposition 3.1. Assume that nr/n → qr > 0 as n → ∞ for r = 0, 1 and let yr(t) =
Pr[X ≥ t | R = r] and yrz(t) = Pr[X ≥ t, Z = z | R = r]. Assume that yr(t), yrz(t) > 0.
Then
√
n
{
δ̂(t)− δ(t)
}
d→ N(0, σ2δ (t)) and
√
n
{
δ̂j(t)− δj(t)
}
d→ N(0, σ2δ (t, j)) as n→∞
where σ2δ (t) = dp
−2
[
var{d̂S(t)} − 2δ(t)cov{d̂S(t), d̂p}+ δ(t)2var(d̂p)
]
,
σ2δ (t, j) = dp
−2
[
var{d̂F j(t)} − 2δj(t)cov{d̂F j(t), d̂p}+ δj(t)2var(d̂p)
]
,
var{d̂S(t)} =
∑
r
σ2r for σ
2
r (t) = Sr(t)
2
∫ t
0
λr(u)
yr(u)
du, var(d̂p) =
∑
r
var(pˆr)
cov{d̂S(t), d̂p} =
∑
r
σr1 for σrz(t) = −Sr(t)
∫ t
0
yrz(u)
yr(u)
{λrz(u)− λr(u)} du,
var{d̂F j(t)} =
∑
r
σ2r (t, j) for σ
2
r (t, j) =
∫ t
0
Sr(t)
2λ
j
r(u)
yr(u)
du− 2
∫ t
0
Sr(u)
λjr(u)
yr(u)
×
{∫ t
u
Sr(s)λ
j
r(s)ds
}
du+
∫ t
0
λr(u)
yr(u)
{∫ t
u
Sr(s)λ
j
r(s)ds
}2
du and
cov{d̂F j(t), d̂p} =
∑
r
σr1(t, j) for σrz(t, j) =
[∫ t
0
Sr(u)
yrz(u)
yr(u)
{
λjrz(u)− λjr(u)
}
du
−
∫ t
0
yrz(u)
yr(u)
{λrz(u)− λr(u)}
∫ t
u
Sr(s)λ
j
r(s)ds du
]
.
Consistent variance estimators σ̂2δ (t) and σ̂
2
δ (t, j) can be obtained by plugging in consistent
estimators of δ(t), δj(t), σ2r (t), σrz(t), σ
2
r (t, j), σrz(t, j), p1 and p0 for r = 0, 1, and z = 1 in
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the expressions above; specifically
σ̂2r (t) =Ŝr(t)
2
∫ t
0
{
nr
Yr(u)− 1
}
dNr(u)
Yr(u)
, σ̂rz(t) = Ŝr(t)
∫ t
0
{
Yrz(u)dNr(u)
(Yr(u))2
− dNrz(u)
Yr(u)
}
,
σ̂2r (t, j) =
∫ t
0
Ŝr(u)
2
{
nr{Yr(u)− 1}
Yr(u)
}
dN jr (u)
{Yr(u)}2 − 2
∫ t
0
{F̂ jr (t)− F̂ jr (u)}Ŝr(u)
dN jr (u)
Yr(u)
+
∫ t
0
{F̂ jr (t)− F̂ jr (u)}2
dN jr (u)
Yr(u){Yr(u)− 1} and
σ̂rz(t, j) =
∫ t
0
Ŝr(t)
Yrz(u)dN
j
r (u)
{Yr(u)}2 −
∫ t
0
Ŝr(t)
dN jrz(u)
Yr(u)
−
∫ t
0
{F̂ jr (t)− F̂ jr (u)}
Yrz(u)dNr(u)
{Yr(u)}2
+
∫ t
0
{F̂ jr (t)− F̂ jr (u)}
dNrz(u)
Yr(u)
.
The estimator σ̂2r (t) is the usual Greenwood estimator of the variance of Sˆr(t). The estima-
tor σ̂2r (t, j) is the estimator of the variance of F̂
j
r (t) proposed in Gaynor et al. (1993) (which
most accurately estimates the true variance of F̂ jr (t) when compared to several competing es-
timators according to the simulation study in Braun and Yuan, 2007). Using Proposition 3.1,
a 100(1−α)% confidence interval for δ(t) is given by δ̂(t)± zα/2σ̂δ(t)/
√
n and a 100(1−α)%
confidence interval for δj(t) is given by δ̂j(t) ± zα/2σ̂δ(t, j)/
√
n where z1−α/2 is the 1 − α/2
quantile of a standard normal variate. A proof of Proposition 3.1 is contained in Appendix
A.1.
3.3.2 Hypothesis Testing
To conduct tests of any difference between the two treatment groups in the survival curves
and subdistribution curves for cause j, consider testing the following hypotheses
H0 : δw(t0) =
∫ t0
0
w(u)δ(u)du = 0 and Hj0 : δ
j
w(t0) =
∫ t0
0
w(u)δj(u)du = 0
for t0 ∈ (0, τ) and where w is a user defined weight function.
Proposition 3.2. Suppose there exists a non-negative function W such that for some t ∈
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[0, t0), assume that
sup
t∈[0,t0]
∣∣∣Ŵ (t)− w(t)∣∣∣ p→ 0 as n→∞.
Then for the null hypotheses H0 : and H
j
0 : we have that
under H0,
√
n
{
δ̂w(t0)− δw(t0)
}
du
d→N(0, σ2w(t0)) as n→∞ and
under Hj0 ,
√
n
{
δ̂jw(u)− δjw(u)
}
du
d→N(0, σ2w(t0, j)) as n→∞
where δ̂w(t0) =
∫ t0
0
Ŵ (u)δ̂(u)du, δ̂jw(t0) =
∫ t0
0
Ŵ (u)δ̂j(u)du,
σ2w(t0) = dp
−2
 t0∫
0
{∫ t0
t
w(u)S(u)du
}2 {
y0(t)
−1 + y1(t)−1
}
λ(t)dt
 and
σ2w(t0, j) = dp
−2
 t0∫
0
{∫ t0
t
w(u)du
}2 {
y0(t)
−1 + y1(t)−1
}
dσ2(t, j)
 .
Further, σ2w(t0) and σ
2
w(t0, j) may be consistently estimated by
σ̂2w(t0) = d̂p
−2∑
r
t0∫
0
{∫ t0
t
Ŵ (u)Ŝr(u)du
}2{
nr
(Yr(u)− 1)
}
dNr(u)
Yr(u)
and
σ̂2w(t0, j) = d̂p
−2∑
r
t0∫
0
{∫ t0
t
Ŵ (u)du
}2
dσ̂2r (u, j).
Weighted instrumental variables (WIV) tests with rejection regions defined by
Q =
{
δ̂w(t0) :
∣∣∣√nδ̂w(t0)/σ̂w(t0)∣∣∣ > z1−α/2} and
Qj =
{
δ̂jw(t0) :
∣∣∣/√nδ̂jw(t0)/σ̂w(t0, j)∣∣∣ > z1−α/2}
provide unbiased 2-sided size α tests of H0 : δw(t0) = 0 and H
j
0 : δ
j
w(t0) = 0.
Rejection of the WIV test for H0 indicates that the effect of treatment on the all-cause
survival experience within the ZP0 = (0, 1) principal strata is nonzero.
Rejection of the WIV test for Hj0 indicates that the effect of treatment on the cumulative
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incidence of the event due to cause j is nonzero. Similar to the estimands in (3.2) and (3.4),
δw(t) =
∑J
j=1δ
j
w(t). Again, the effect of treatment on one cause j may cancel with the effect
of treatment on another cause j′ such that the hypothesis of no treatment effect on the all
cause survival H0 is null, but the cause specific hypotheses of no treatment effect H
j
0 and
Hj
′
0 are not null. Therefore the availability of unbiased tests of H
j
0 for j = 1, . . . , J allows
for testing of treatment effects on cause specific subdistributions that may have been missed
if only a test of a treatment effect on the all cause survival H0 were conducted. A proof of
Proposition 3.2 is contained in Appendix A.2.
3.4 Simulation Study
Simulations were conducted under Asssumptions 3.1–3.7. For each simulated data set n
principal strata vectors ZP0 were simulated using a multinomial random number generator
with parameter θ = (θ00, θ01, θ10, θ11) with θij = Pr[Z
P0 = (i, j)]; (θ10 = 0 under Assumption
3.5). The parameter θ01 is the proportion of the population that are in the compliers principal
strata and provides a measure of the strength of the instrument in determining treatment
allocation. The randomized treatment assignment R was simulated by randomly permuting
a vector of size n containing 0 p0n times and 1 for the p1n remaining entries. The random
variable Z was determined based on R and ZP0 . Censoring times C were generated using
a uniform random number generator on the interval (CR, CR + ∆CR). The time to the
first event T (Z) = T was simulated by sampling from the distribution defined by an overall
hazard of
∑J
j=1 λ
j
rz(t) where each λ
j
rz(t) is a Weibull hazard of the form κγ(γt)κ−1 for various
scenarios as detailed in Table 3.1. The event indicator ∆ was simulated by sampling from a
multinomial random variable with Pr[∆ = j|T ] = λjrz(T )/
∑J
j=1 λ
j
rz(T ) for j = 1, 2. If the
subject was censored, ∆ was set to 0. All results are based on 5,000 Monte Carlo simulations,
p0 = 0.5, C0 = 4, ∆C0 = 6, C1 = 3, ∆C1 = 3, w(t) = 1 and t0 = min{maxi(Xi|Ri = 0),
maxi(Xi|Ri = 1)}.
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Naive “as treated” analysis about (3.1) and (3.3) might entail computing the estimators
δ˜(t) = Ŝ11(t)− Ŝ00(t) and δ˜j(t) = F̂ j00(t)− F̂ j11(t) (3.5)
where Ŝrz(t) and F̂
j
rz(t) are the Kaplan Meier estimator of the survival function and the
Aalen Johansen estimator of the subdistribution function conditional on R = r and Z =
z. Pointwise confidence intervals for (3.1) and (3.3) might be computed by appealing to
asymptotic normality results (Andersen et al., 1995) for Ŝrz(t) and F̂rz(t). In this “as treated”
analysis, testing the hypotheses H0 and H
j
0 might be accomplished using weighted Kaplan
Meier (WKM) tests as in Pepe and Fleming (1989). The coverage of the pointwise confidence
intervals for δ(t) and δj(t) and power of the WIV tests for H0 and H
j
0 in Propositions 3.1 and
3.2 are compared to the coverage of pointwise confidence intervals and the power of WKM
tests in this naive analysis.
Nonproportional hazards in the treated versus the control amongst the complier principal
strata are assumed in all scenarios. Scenario 1 describes a situation in which one cause (j = 2)
exhibits a causal treatment effect in the complier principal strata. In this scenario, the power
to reject H20 is similar to H0 and the power of H
1
0 is small (though note that this scenario is
not null, i.e. H10 : δ
1
w(t0) 6= 0). Scenario 2 describes a situation in which both causes exhibit
causal treatment effects, but these effects cancel each other out such that δw(t0) = 0 (as
described in Section 3.2.3 and at the end Section 3.3.2). The power to reject H0 in Scenario
2 reflects that this test is consistent and the type I error is controlled. These opposing causal
effects for j = 1 and 2 are roughly the same magnitude as δ2w(t0) in Scenario 1, and the power
to reject both H10 and H
2
0 in Scenario 2 is similar to the power to reject H
2
0 in Scenario 1.
Scenario 3 describes a situation in which both causes exhibit a causal treatment effect that are
the same sign and magnitude. As would be expected, the power to reject H0 in this situation
is higher than that of H10 or H
2
0 , which are roughly the same. Scenario 4 describes a situation
in which there are no causal treatment effects in the complier principal strata for cause 1 or 2
such that δw(t0) = δ
1
w(t0) = δ
2
w(t0) = 0. Again, as expected the results here demonstrate that
the tests of H0, H
1
0 and H
2
0 are consistent. In all scenarios the strength of the instrument (as
67
measured by θ01 – the proportion of the population who are compliers) has large effects on
the power of the test, with increasing instrument strength yielding increased power.
The power for the corresponding naive weighted Kaplan Meier tests are higher, however,
these tests are not unbiased. The estimated power is greater than 5% in the scenarios where
the treatment effect is null (Scenario 4, and Scenario 2 for j = (all)), meaning that these
tests have inflated type I error and therefore should not be used to test for the local average
treatment effects in (3.1) and (3.3).
Table 3.2 shows that the IV estimators δ̂(t) and δ̂j(t) are unbiased and that the variance
estimators accurately estimate the true variance (as indicated by the ratio of the average
estimated variance and the empirical standard error). The coverage of the IV pointwise
confidence intervals exhibit the ideal 0.95 in almost all scenarios (though there is slight over
coverage in Scenario 2 for δ1(t) where the treatment effect in the compliers principal strata
has the opposite sign of that of the difference between the always treated and never treated
principal strata). On the other hand, the naive “as treated” estimators δ˜(t) and δ˜j(t) have
higher bias and the coverage for the corresponding confidence intervals is poor in several
scenarios (e.g., see Scenario 2, j = 1 or Scenario 4, for all j). The power to reject Hj0(t) :
δj(t) = 0 based on the IV pointwise confidence intervals gives similar results as what was
seen in Table 3.1, particularly for t = 5. These tests are again unbiased as indicated by the
null scenarios yielding estimated power of approximately 5%. However, testing Hj0(t) using a
naive analysis again results in inflated type I error.
3.5 Application to the BAN Study
In this section the methods devleoped in Section 3.3 are employed to compare cumulative
incidence of HIV or death in the infant NVP arm and the maternal ARV arm to the control
group in the BAN study. Treatment Z is the actual treatment taken based on the randomized
assignment R and the treatment compliance surveys taken in the weeks following random-
ization. A subject was considered noncompliant (i.e., Z = 0) if any pills were reported as
missed on the first completed treatment compliance survey. In the maternal ARV arm, 12%
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of subjects met this criteria and in the infant NVP arm, 5% met this criteria. It was assumed
that no patients in the control arm took either the infant NVP or maternal ARV treatment
regimens which would imply that Assumption 3.5 holds.
The nonparametric IV and naive “as treated” estimates along with corresponding 95%
confidence intervals of δj(t) are given in Table 3.3 for time to HIV infection (j = 1) or death
(j = 2). Figure 3.1 depicts IV estimates of the all cause cumulative incidence functions
partitioned by cumulative incidence of HIV and death for each treatment arm as well as
the results of the WIV tests for H0 and H
j
0 . Table 3.3 and Figure 3.1 show that infant NVP
decreases the probability of both infant HIV infection and death and this result is statistically
significant for the composite endpoint and the HIV infection endpoint. The estimated effect of
maternal ARV is positive for cumulative incidence of HIV, death and the composite endpoint,
however none of these effects are significant based on the pointwise IV confidence intervals.
Table 3.3 and Figure 3.1 also demonstrate that the IV pointwise confidence intervals
and WIV tests give qualitatively similar results to a naive analysis adjusting for compli-
ance (as described in Section 3.5) when comparing the infant NVP arm to control. This
might be expected because the proportion that were compliant in the infant NVP arm was
quite high. However, different conclusions are reached by IV based and naive analyses when
comparing the maternal ARV arm to control for the HIV infection endpoint. Specifically, a
significant positive effect of maternal ARV versus control is found when using the WIV test
(
∣∣∣√nδ̂2w(t0)/σ̂w(t0)∣∣∣ = 1.96, p-value 0.05) whereas the naive WKM test does not reject the null
hypothesis H10 of no treatment effect on cumulative incidence of HIV (Z score 1.67, p-value
0.09). Also, as seen in Table 3.3, the IV based estimates of the difference in cumulative inci-
dence of HIV between maternal ARV and control are roughly 20-30% greater than the naive
estimates. Additionally, at 18 weeks a naive confidence interval for δ(t) for maternal ARV
versus control excludes 0 indicating a significant positive effect of maternal ARV on time to
death or HIV infection, but the IV confidence interval does not exclude 0 and therefore does
not indicate a significant positive effect.
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3.6 Discussion
In this paper large sample properties are derived of nonparametric IV estimators and
global hypothesis test statistics for the local average treatment effects (3.1) and (3.3) for right
censored data in the presence of competing risks. Without competing risks, our proposed test
enables a test for the causal effect on survival at all time points, which contrasts with previous
work on fixed time points. The methods are valid under a wide range of relationships between
the competing causes for the event, for local average treatment effects with nonproportional
hazards and for various scenarios regarding the similarity of the distributions of the time to
the event in the various principal strata. As demonstrated in Table 3.1, weaker instrumental
variables (i.e. smaller proportions of the population whose treatment is determined by the
instrument) yield less powerful WIV global tests of no treatment effect, but the WIV tests
remain consistent for both a stronger and weaker instrumental variable. Also as evidenced
by Table 3.1, naive treatment comparisons similar to those described in Section 3.4 do not
yield valid results for the hypothesis test of no local average treatment effect on the all cause
survival experience or on the cumulative incidence of some specific cause.
As demonstrated by Section 3.5, the use of such naive analyses may result in different
conclusions being drawn about a treatment effect, which may impact important clinical or
policy decisions. In the BAN study rates of non-compliance were low, and application of
the IV methods here demonstrate that even when there is a low rate of non-compliance,
the IV pointwise confidence intervals and WIV tests may yield different results than a naive
analysis, highlighting the importance of using these methods for randomized studies with
non-compliance to treatment assignment and a competing risks outcome. In a study with a
higher rate of non-compliance the amount of discordance between the two analyses will likely
increase.
Though the results here are valid for any instrumental variable meeting Assumptions 3.1–
3.5 and 3.7, finding an instrumental variable that is unrelated to the outcome may be difficult.
Relaxing Assumption 3.7 such that the instrumental variable R is independent of the outcome
conditional on some set of covariates might allow for more candidate instrumental variables to
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choose from. Additionally, treatment effects adjusted for covariates might also be desired. In
this paper compliance is simplified to an all or nothing binary measure; however, in many real
world applications compliance may be more complicated with some subjects being partially
compliant. Thus results that allow for a more general form of the either the instrumental
variable R or the treatment received Z may also be useful. The use of multiple weaker
instrumental variables to identify local average treatment effects might also have utility in
many real world applications (Hahn et al., 2004; Hausman et al., 2012).
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Table 3.1: Simulation scenarios for T (Z) for ZP0 in presence of competing risks (J = 2) and
power of a size α = 0.05 WIV test of H0 : δ
j
w(t0) = 0 and the naive WKM test discussed in
Section 3.4 for n = 300, 1000, 2000. Results are based on θ = ([1−θ01]/2, θ01, 0, [1−θ01]/2) for
various θ01. The hazard for each j within each Z
P0 has Weibull hazard of the form κγ(γt)κ−1
for parameters (γ, κ). For ZP0 = (1, 1), (γ, κ) = (0.10, 1) for j = 1, 2 and for ZP0 = (0, 0),
(γ, κ) = (0.16, 1) for j = 1, 2.
(γ, κ) for Power Hj0 : δ
j
w(t0)=0
ZP0 = (0, 1) WIV Naive WKM
Scen- n= n=
ario θ01 j z=0 z=1 300 1000 2000 300 1000 2000
1 0.6 1 (0.12,1.2) (0.12,1.2) 5 8 14 83 98 14
2 (0.24,1.2) (0.12,1.2) 63 95 99 90 100 100
(all) 56 97 100 89 100 100
0.3 1 (0.12,1.2) (0.12,1.2) 4 4 4 59 93 98
2 (0.24,1.2) (0.12,1.2) 20 51 80 20 51 80
(all) 19 50 78 79 99 100
2 0.6 1 (0.1,1.2) (0.2,1.2) 59 96 99 87 99 100
2 (0.3,1.2) (0.2,1.2) 65 97 99 89 100 100
(all) 6 6 6 17 45 74
0.3 1 (0.1,1.2) (0.2,1.2) 18 45 74 18 45 74
2 (0.3,1.2) (0.2,1.2) 20 50 76 20 50 76
(all) 6 5 5 34 83 99
3 0.6 1 (0.19,1.2) (0.12,1.2) 14 35 61 30 69 90
2 (0.19,1.2) (0.12,1.2) 15 35 61 15 35 61
(all) 62 98 100 91 100 100
0.3 1 (0.19,1.2) (0.12,1.2) 6 10 17 13 20 29
2 (0.19,1.2) (0.12,1.2) 8 10 17 17 19 31
(all) 21 55 84 42 94 100
4 0.6 1 (0.2,1.2) (0.2,1.2) 4 3 2 6 9 10
2 (0.2,1.2) (0.2,1.2) 5 3 3 6 10 12
(all) 6 5 5 13 32 58
0.3 1 (0.2,1.2) (0.2,1.2) 4 3 3 5 7 9
2 (0.2,1.2) (0.2,1.2) 5 3 2 5 7 9
(all) 5 5 5 5 17 31
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Table 3.2: Simulation results: bias (× 100), empirical standard error (ESE) (× 100), the
ratio of the average estimated standard error and the empirical standard error (ESE Ratio,
%), coverage of pointwise 95% confidence intervals for δj(t) and the percent power to reject
Hj0(t) : δ
j(t) = 0 (%) based on (i) the IV estimators and pointwise confidence intervals and
(ii) the naive estimators and confidence intervals for simulation Scenarios 1–4 as described in
Table 3.1 for θ01 = 0.6 and n = 1000.
Scen- Bias ESE ESE Ratio Coverage Power
ario j t δ̂j(t) δ˜j(t) δ̂j(t) δ˜j(t) δ̂j(t) δ˜j(t) δ̂j(t) δ˜j(t) δ̂j(t) δ˜j(t)
1 1 3 -0.2 2.9 4.4 3.0 104 99 96 84 11 6
5 -0.2 4.1 5.2 3.4 105 101 96 79 31 21
2 3 0.2 -3.3 5.0 3.6 94 90 93 82 99 100
5 0.2 -4.3 5.6 3.7 95 98 93 79 100 100
(all) 3 0.0 -0.4 5.3 3.5 100 101 95 95 93 100
5 0.0 -0.3 5.2 3.4 100 101 95 95 92 100
2 1 3 -0.1 7.0 4.6 3.1 110 97 97 36 98 97
5 -0.1 8.5 5.3 3.5 112 99 97 30 99 100
2 3 0.1 -2.8 5.2 3.7 94 92 93 87 97 100
5 0.1 -4.2 5.6 3.7 93 99 93 79 99 100
(all) 3 0.0 4.1 5.2 3.4 100 102 95 78 6 22
5 0.0 4.2 4.8 3.0 100 101 95 72 5 28
3 1 3 -0.3 -0.5 4.8 3.3 97 95 94 94 54 84
5 -0.1 -0.3 5.5 3.7 97 98 94 94 41 70
2 3 0.0 -0.4 4.8 3.3 96 96 94 94 57 85
5 0.1 -0.2 5.6 3.7 96 99 94 95 43 70
(all) 3 -0.2 -0.9 5.1 3.4 103 103 96 95 96 100
5 0.0 -0.6 5.1 3.4 102 101 96 95 95 100
4 1 3 0.1 2.3 5.0 3.5 98 93 95 88 5 12
5 0.0 2.3 5.5 3.7 100 99 95 90 5 10
2 3 -0.1 2.2 5.0 3.5 99 93 94 89 6 11
5 -0.1 2.2 5.6 3.8 98 97 95 90 5 10
(all) 3 0.1 4.4 5.3 3.5 98 98 94 74 6 26
5 0.0 4.4 4.9 3.1 98 99 95 69 5 31
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Table 3.3: Results for the BAN study: IV δˆj(t) and naive δ˜j(t) estimates (×100) and
corresponding 95% confidence intervals for (a) infant NVP versus control and (b) maternal
ARV versus control and for endpoints of infant HIV infection (j = 1), death (j = 2) and HIV
infection or death (all j).
Treatment Comparison
(a) Infant NVP (b) Maternal ARV
Endpoint vs control vs control
t δ̂j(t) (95% CI) δ˜j(t) (95% CI) δ̂j(t) (95% CI) δ˜j(t) (95% CI)
HIV infection (j = 1)
6 weeks 1.60 (0.56, 2.64) 1.53 (0.54, 2.52) 0.69 (-0.68, 2.07) 0.60 (-0.63, 1.84)
18 weeks 3.31 (1.76, 4.86) 3.16 (1.67, 4.65) 1.79 (-0.19, 3.76) 1.59 (-0.19, 3.36)
28 weeks 3.41 (1.56, 5.25) 3.36 (1.60, 5.12) 2.20 (-0.01, 4.42) 1.88 (-0.13, 3.88)
48 weeks 2.55 (0.19, 4.92) 2.59 (0.32, 4.85) 2.07 (-0.58, 4.72) 1.71 (-0.70, 4.12)
Death (j = 2)
6 weeks 0.40 (-0.26, 1.05) 0.37 (-0.26, 1.01) 0.28 (-0.49, 1.06) 0.36 (-0.29, 1.01)
18 weeks 0.69 (-0.61, 1.98) 0.61 (-0.66, 1.87) 0.43 (-1.05, 1.91) 0.80 (-0.44, 2.04)
28 weeks 1.12 (-0.55, 2.78) 0.98 (-0.64, 2.60) 1.05 (-0.80, 2.89) 1.44 (-0.13, 3.00)
48 weeks 1.55 (-0.59, 3.68) 1.34 (-0.74, 3.42) 2.01 (-0.29, 4.30) 2.35 (0.38, 4.32)
HIV infection or death (all)
6 weeks 2.00 (0.77, 3.22) 1.90 (0.73, 3.08) 0.98 (-0.59. 2.55) 0.96 (-0.43, 2.35)
18 weeks 4.00 (2.00, 6.00) 3.76 (1.83, 5.70) 2.22 (-0.21. 4.65) 2.39 (0.24, 4.53)
28 weeks 4.52 (2.07, 6.97) 4.34 (1.98, 6.70) 3.25 (0.43. 6.07) 3.31 (0.80, 5.82)
48 weeks 4.10 (0.98, 7.22) 3.93 (0.91, 6.94) 4.08 (0.68. 7.47) 4.06 (1.01, 7.11)
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Figure 3.1: Application to the BAN study: cumulative incidence estimates partitioned by
cause and results of the hypothesis tests of no treatment effect on cumulative incidence of HIV,
H10 : δ
1
w(t0) = 0; no treatment effect on death, H
1
0 : δ
2
w(t0) = 0; and no effect of treatment on
death or cumulative incidence of HIV, H0: δw(t0) = 0 based on the WIV tests in Proposition
3.2 for (a) infant NVP versus control and (b) maternal ARV versus control.
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CHAPTER 4: IDENTIFICATION OF TREATMENT EFFECTS WITH
INTERFERENCE USING INSTRUMENTAL VARIABLES
4.1 Introduction
When studying causal effects of a treatment or exposure, sometimes the treatment or ex-
posure received by one individual may affect the outcomes of other individuals under study.
This is referred to as interference and is most frequently encountered in settings in which
outcomes are largely dependent on social happenings. Some well known examples of settings
where this might occur include the study of infectious diseases and vaccination, educational
interventions, and effects of housing voucher programmes. Until recently, most causal infer-
ence research has operated under the assumption that there is no interference between units
(Cox, 1958), which is part of the assumption commonly known as the stable unit treatment
value assumption or SUTVA (Rubin, 1980). In the aforementioned settings, this assumption
is undoubtedly violated. Moreover, effects due to interference between units are often a target
of inference useful in determining important social and public health policies, where policy
makers must consider the totality of an effect of a treatment or exposure, not just the effect
it has at the individual level.
Though most causal inference operates under the assumption of no interference, Rubin
(1980) noted that the potential outcomes framework could be extended to accommodate
interference between units. Drawing inference about treatment effects in the presence of in-
terference has since become an active area of research, especially in the last decade (Halloran
and Struchiner, 1995; Hong and Raudenbush, 2006; Sobel, 2006; Rosenbaum, 2007; Hudgens
and Halloran, 2008; Aronow and Samii, 2011; Tchetgen Tchetgen and Vanderweele, 2012;
Bowers et al., 2012). Though the advancements made account for interference and define new
causal effects describing the level of interference, many of the results obtained assume a two
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stage randomized experiment (randomizing both individuals as well as groups of individuals to
different treatment allocation strategies). Two stage randomized experiments are sometimes
difficult, impractical or unethical to implement in practice, thus adaptations to these methods
for use with observational data or for randomized designs not necessarily having randomiza-
tion at both the group and the individual level may have great utility. Hong and Raudenbush
(2006) proposed estimators that stratify by the z-score of the propensity model to estimate
interference effects in observational data. Tchetgen Tchetgen and Vanderweele (2012) pro-
posed inverse probability of treatment weighted estimators that Perez-Heydrich et al. (2014)
demonstrate consistently estimate causal interference effects in observational settings. Both
the stratified and inverse probability weighted approaches rely on the assumption that there
is no unmeasured confounding with regard to treatment selection. If such an assumption is to
be avoided, many of the causal interference effects are in general not identifiable if treatment
assignment is not randomized at either the group or individual level. Manski (2013) delin-
eates partial identification results under general interference and describes various classes of
bounding assumptions which shrink the identification regions obtained. These results lay a
foundation for identification of causal effects under interference.
In this article, we assume individuals can be partitioned into groups such that there may
be interference between individuals in the same groups but there is no interference between
individuals in different groups. Under this assumption, identification results are derived for
direct, indirect, and total effects of treatment in the presence of interference under various
assumptions. These results may be used in observational settings where there exist variables
that are only associated with the outcome through their effect on treatment allocation, which
are commonly known as instrumental variables. These bounds might also be applicable to
randomized studies where an instrumental variable may be available (e.g. a randomized
encouragement design). We also derive consistent estimators of the derived bounds and
estimands. The remainder of this article is organized as follows. In Section 4.2, the notation
and a few key assumptions are introduced. Section 4.3 defines the direct, indirect and total
effects of treatment. In Section 4.4, bounds for these three causal effects are derived under
varying sets of assumptions. Section 4.5 discusses estimation of the bounds and Section 4.7
77
presents the motivating example on rotavirus vaccination amongst U.S. infants and applies
the obtained results. Section 4.8 concludes with a discussion.
4.2 Notation, Potential Outcomes and Assumptions
Suppose we have a random sample (from some super population) of N groups of individ-
uals each containing ni individuals for i = 1, . . . , N . Let Zij denote the treatment selected
(or received) by individual j in group i where Zij = 1 indicates treatment selected and 0
indicates treatment not selected. Let Zi,−j be the proportion of individuals in group i other
than individual j that are treated and Zi the proportion of individuals treated in group i.
At the individual level we are interested some binary outcome Yij . For instance, Yij may
indicate whether or not an infection of interest occurred where Yij = 1 indicates that the
individual becomes infected and Yij = 0 otherwise. Let the individual potential outcomes
be denoted Yij(zij , zi,−j , rij) for zij = 0, 1, zi,−j ∈ [0, 1] and rij ∈ R, allowing for different
potential outcomes for each individual treatment choice zij , each value of the proportion
of other individuals in the group treated zi,−j and each value of the instrumental variable
rij (further discussed below). The potential outcomes are assumed to remain constant with
changes in the treatment status of members of other groups; this assumption has been referred
to as partial interference (Sobel, 2006) or constant treatment response (Manski, 2013). This
assumption is reasonable if interaction between members of different groups is minimal or
nonexistent and will be made throughout the remainder of this paper. The potential outcomes
are also assumed to remain constant regardless of which specific members of the individual’s
group are treated. This has been referred to as stratified interference (Hudgens and Halloran,
2008). Let Zij be the set of all possible realizations of the vector (Zij , Zi,−j , Rij) and denote
the set of all possible potential outcomes for individual j in group i as Yij(Zij). Finally, let Vi
be some set of measured group level covariates that might confound the relationship between
(Zij , Zi,−j) and Yij(Zij).
Assumptions 4.1–4.2 introduced below for j = 1, . . . , ni and i = 1, . . . , N are assumed
throughout the rest of the paper.
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Assumption 4.1. Causal consistency: if Zij = zij, Zi,−j = zi,−j and Rij = rij, then
Yij(zij , zi,−j , rij) = Yij and Zij(rij) = Zij for zij = 0, 1, rij ∈ R and for all zi,−j.
Assumption 4.1 connects the observed outcomes to the potential outcomes. It states that
the observed outcome is equal to the potential outcome under the observed treatment Zij ,
observed proportion of other group members treated Zi,−j , and instrumental variable Rij .
Assumption 4.2. Positivity: dFZi,−j ,Zij (z, zi,−j) > 0 for z = 0, 1 and all zi,−j.
Here FZi,−j ,Zij (z, zi,−j) denotes the joint distribution of Zi,−j , Zij at (z, zi,−j) (in general
let FA,B(a, b) denote the joint distribution of the random variables A and B at (a, b)). As-
sumption 4.2 states that every combination of Zij and Zi,−j is observed as the number of
groups goes to infinity.
In many circumstances an instrumental variable will be available and may provide a means
for arriving at tighter bounds on the causal effects defined in Section 4.3 below. Suppose that
Rij is some instrumental variable taking finitely many values in some set R. Assumptions 4.3–
4.6 below are analogous to the assumptions made in Imbens and Angrist (1994) and Angrist
et al. (1996) to estimate average treatment effects when an instrumental variable is available
(in the absence of interference). A variable Rij will qualify as an instrumental variable if
it meets Assumptions 4.3–4.5 below. Here assume that each individual in each group has
potential treatment outcomes Zij(rij) for each level of this instrumental variable rij ∈ R.
Assumption 4.3. Nonzero causal effect of Rij on Zij: E[Zij(r)− Zij(r′)] 6= 0 for r 6= r′.
Assumption 4.4. Exclusion restriction : Yij(zij , zi,−j , rij) = Yij(zij , zi,−j , r′ij) for zij = 0, 1,
rij , r
′
ij ∈ R and all zi,−j
Assumption 4.3 states that the instrumental variable has some effect on treatment selection
and Assumption 4.4 states that the instrumental variable has no effect on the potential
outcomes for Yij for fixed zij and zi,−j . Assumptions 4.3 and 4.4 together imply that Rij only
affects the potential outcomes Y(Zij) through its effect on treatment selection.
Assumption 4.5. Independent instrument: Rij q {Yij(Zij), Zij(rij)} for rij = 0, 1}
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Assumption 4.5 states that the distribution of the observed value of instrumental variable
does not depend on the potential outcomes Y(Zij). This assumption might be considered
valid for variables Rij such as calendar time, randomized encouragement to take treatment,
or randomized treatment assignment.
Assumption 4.6. Monotonicity of rij on Zij: Zij(rij) ≥ Zij(r′ij) for rij > r′ij ∈ R
Under Assumption 4.6 there are no individuals that would be treated under smaller values
of r but not under larger values of r. For a variable corresponding to calendar time of
enrollment in a study, this assumption indicates that there are no individuals who would get
treated if they enrolled earlier, but not if they enrolled later.
When there is no interference, an ideal instrumental variable to estimate the average
treatment effect is given by the individual randomized treatment assignment (assuming no
noncompliance to treatment assignment). As mentioned in the Introduction, when there is
interference the gold standard for estimating causal effects is achieved by randomly assigning
groups to different treatment allocation programmes p, meaning that Zi is randomly assigned,
and then randomly assigning Zij based on Zi. Thus an ideal instrumental variable is given
by Rij = (R
p
i , R
z
ij) where R
p
i is the group treatment allocation strategy assignment and R
z
ij
is the individual level treatment assignment based on Rpi (again assuming no noncompliance
to treatment assignment).
4.3 Causal Estimands
Often it is of interest in public health to draw inference about the relative effectiveness of
different group wide treatment allocation programmes. For example, policy makers might be
interested in the effect of vaccinating 90% of school aged children compared to vaccinating a
smaller percentage on the incidence of some childhood disease. Consider two treatment allo-
cation programmes p = 0, 1 where the proportion of individuals in a group that are treated
under programme p follows some distribution indexed by parameter αp denoted FZ(z|αp).
Causal effects in the presence of interference can be defined as contrasts between average
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potential outcomes under a particular treatment programme and individual treatment sta-
tus (Sobel, 2006; Hudgens and Halloran, 2008; Tchetgen Tchetgen and Vanderweele, 2012).
Specifically, for individual j in group i, define the individual average potential outcome under
αp as
Y ij(z, αp, r) =
1∫
0
Yij(z, zi,−j , r)dFZi,−j |Zij (zi,−j |z;αp). (4.1)
where FZi,−j |Zij (zi,−j |z) is the conditional distribution of Zi,−j given Zij = z (in general
let FA|B(a|b) denote the distribution of the random variable A at a given B = b). Under
Assumption 4.4, Y ij(z, αp, r) = Y ij(z, αp, r
′) for r, r′ ∈ R which we denote by Y ij(z, αp).
Define E[Y ij(z;αp)] to be the mean individual average potential outcome (in the super-
population) under individual treatment status z and group treatment allocation programme
p.
As delineated by Halloran and Struchiner (1995), several effects may be of interest when
studying interference. Direct effects study the effect of treatment (z = 1 compared to z = 0)
while holding the treatment allocation strategy fixed. Indirect effects compare the effect of
different treatment programmes (p = 1 compared to p = 0) while holding the treatment
constant. These are also referred to as spillover effects (Sobel, 2006; Tchetgen Tchetgen and
Vanderweele, 2012). For the purposes here, we are only interested in indirect effects for the
untreated z = 0. T otal effects compare the effects of treatment (z = 1 compared to z = 0)
while also comparing treatment allocation strategies. Formally, define
DE(α0) = E[Y ij(0;α0)]− E[Y ij(1;α0)]
IE(α0, α1) = E[Y ij(0;α0)]− E[Y ij(0;α1)]
TE(α0, α1) = E[Y ij(0;α0)]− E[Y ij(1;α1)] (4.2)
to be the direct, indirect and total effects. Assumptions 4.3–4.9 introduced above and below
are used to bound or identify the causal effects defined in (4.2).
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Assumption 4.7. No unmeasured confounding for other group members treatment: Yij(Zij)q
Zi,−j |{Vi, Rij}
Assumption 4.7 will be valid if all variables that confound the relationship between Zi,−j
and Yij(Zij) are measured in Vi and Rij . Because Zi,−j pertains to the treatment selections of
other individuals, this assumption might be considered valid for a rich enough set of covariates
Vi, perhaps containing only group level demographic information.
Assumption 4.8. No unmeasured confounding for individual treatment: Yij(Zij) q Zij |
{Vi, Rij , Zi,−j}
Assumption 4.8 will be valid if all variables that confound the relationship between Zij
and the potential outcomes Yij(Zij) are measured in Vi and Rij for Zi,−j . However, there
may exist unmeasured individual level factors that confound this relationship, meaning that
Assumption 4.8 might be considered less plausible than Assumption 4.7 for Vi containing only
group level and/or demographic covariates (as will be the case with the rotavirus vaccine data
examined in Section 4.7).
Assumption 4.9. Constant direct effect across Rij: E[Y ij(0, αp, r) − Y ij(1, αp, r)|Zij =
z,Rij = r] = E[Y ij(0, α0, r)− Y ij(1, α0, r)|Zij = z,Rij = r′] for all r 6= r′ and p = 0, 1.
Assumption 4.9 will be valid if the direct effect remains constant amongst those individuals
who selected treatment z across the strata defined by the instrumental variable. Assumptions
similar to Assumption 4.9 are considered in Herna´n and Robins (2006) are used to identify
the average treatment effect using an instrumental variable in the absence of interference.
4.4 Identification Results
Bounds for DE(α0), IE(α0, α1) and TE(α0, α1) under some subset of Assumptions 4.1–4.9
can be found by formulating optimization problems maximizing and minimizing E[Y ij(z;αp)]
for z, p = 0, 1 subject to the constraints imposed by the subset of assumptions.
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Result 4.1. Under Assumptions 4.1–4.2 and 4.7–4.8, the upper and lower bounds for E[Y ij(z;αp)]
are both given by
µIPW (z, αp) = {dFZij |Vi(Zij |Vi, Rij)}−1Y wij (z, αp;Vi) (4.3)
where
Y wij (z, αp;Vi, Rij) =
dFZi,−j |Zij (Zi,−j |Zij ;αp)
dFZi,−j |Vi,Rij (Zi,−j |Vi, Rij)
I(Zij = z)Yij
and thus E[Y ij(z;αp)] is identified as are DE(α0), IE(α0, α1) and TE(α0, α1).
A proof of Result 4.1 is given in Appendix B.1.
Result 4.2. Under Assumptions 4.1–4.7, a sharp lower bound for E[Y ij(z;αp)] is given by
µLB(z, αp) = E
[
max
r∈R
{
E
[
Y wij (z, αp;Vi, r)
]}]
(4.4)
and a sharp upper bound is given by
µUB(z, αp) =E
[
min
r∈R
{
E
[
Y wij (z, αp;Vi, r) + dFZij |Vi,Rij (1− Zij |Vi, r)
]}]
(4.5)
The bounds µLB(z, αp), µ
LB(z, αp) reduce to the bounds in Manski (1990) if there is no
interference (i.e. ni = 1 for all subjects). The length of these bounds (upper minus lower) is
at most minr 6=r′∈R{Pr[Zij = 0|Rij = r] + Pr[Zij = 1|Rij = r′}, which would be the rate of
noncompliance for Rij given by randomized treatment assignment.
Result 4.3. Under Assumptions 4.1–4.7 and 4.9 it follows that
TEIV (α0, α1) =(drE[Zij ])
−1 {E [Y wij (α0;Vi, Rij)|Rij = rl]− E [Y wij (α1;Vi, Rij)|Rij = ru]}
IEIV (α0, α1) =
{
E
[
Y wij (α0;Vi, Rij)− Y wij (α1;Vi, Rij)|Rij = rl
]
E[Zij |Rij = ru]
−E [Y wij (α0;Vi, Rij)− Y wij (α1;Vi, Rij)|Rij = ru]E[Zij |Rij = rl]}
DEIV (α0) =TE
IV (α0, α1)− IEIV (α0, α1) (4.6)
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where
drE[Zij ] = E[Zij |Rij = ru]− E[Zij |Rij = rl]
Y wij (αp;Vi, Rij) =
dFZi,−j |Zij (Zi,−j |Zij ;αp)
dFZi,−j |Vi,Rij (Zi,−j |Vi, Rij)
Yij .
In absence of interference IEIV (α0, α1) = 0 and TE
IV (α0, α1) = DE
IV (α0) which is the
instrumental variable estimand of Imbens and Angrist (1994).
4.5 Estimation
Under Assumptions 4.1–4.2 and 4.7–4.8 a consistent estimator of µIPW (z, αp) is
µ̂IPW (z, αp) =
1∑N
i=1 ni
N∑
i=1
ni∑
j=1
{dFZij |Vi,Rij (Zij |Vi, Rij)}−1Ŷ wij (z, αp;Vi, Rij) (4.7)
where
Ŷ wij (z, αp;Vi) =
dFZi,−j |Zij (Zi,−j |Zij ;αp)
d̂FZi,−j |Vi,Rij (Zi,−j |Vi, Rij)
I(Zij = z)Yij .
Here d̂FZij |Vi,Rij (Zij |Vi, Rij) and d̂FZi|Vi,Rij (Zi,−j |Vi, Rij) are found by fitting correctly spec-
ified parametric models for Z¯i and Zij . The estimator µ̂
IPW (z, αp) is similar to the IPW
estimator found in Tchetgen Tchetgen and Vanderweele (2012) under stratified interference
and allowing for the a continuous distribution of Zi,−j . Under Assumptions 4.1–4.7, a con-
sistent estimator of µLB(z, αp) is
µ̂LB(z, αp) =
∫
Vi∈V
max
r∈R
{
Ê
[
Ŷ wij (z, αp;Vi, r)
]}
d̂F Vi(Vi)
where V is the set of all possible Vi and Ê[minr∈R{·}] can be found by taking sample means
within strata defined by Rij = r or by fitting a correctly specified parametric model when
84
Rij may take on many possible values. Similarly, a consistent estimator of µ
UB(z, αp) is
µ̂UB(z, αp) =
∫
Vi∈V
min
r∈R
{
Ê
[
Ŷ wij (z, αp;Vi, r)
]
+ d̂FZij |Vi,Rij (1− Zij |Vi, r)
}
d̂F Vi(Vi). (4.8)
A consistent estimator of TEIV (α0, α1), IE
IV (α0, α1) and DE
IV (α0) can be found by plugging
in in consistent estimators for E[Zij |Rij = r] and E [Y w(αp)|Rij = r], which both may be
found by taking sample means of Zij and Ŷ
w
ij (αp;Vi, Rij) within strata defined by Rij = r or
by fitting correctly specified parametric models for Zij and Y
w
ij (αp;Vi, Rij)) if Rij has many
levels. Here
Ŷ wij (αp;Vi, Rij) =
dFZi,−j |Zij (Zi,−j |Zij ;αp)
d̂FZi,−j |Vi,Rij (Zi,−j |Vi, Rij)
Yij .
4.6 Simulation Study
Simulations were conducted under various sets of Assumptions 4.1–4.9 for ni = 60 indi-
viduals for all i in N = 300 groups. For each individual in each group a binary instrumental
variable Rij meeting meeting assumptions 4.3–4.5 was simulated using a Bernoulli random
number generator. The mean coverage for each group Zi was simulated using a beta ran-
dom number generator with mean dependent on a binary group level covariate Vi. Individual
treatment Zij |Zi was simulated using a Bernoulli random number generator with mean Zi.
For each individual the potential treatment outcome under the unobserved value of the in-
strument was also simulated yielding the vector ZP0ij = (Zij(0, Zij(1)) for each individual in
each group. A binary outcome Yij = Yij(Zij , Zi,−j) was simulated using a Bernoulli random
number generator that depends on Zi,−j and ZP0ij .
Estimates of DE(0.25), IE(0.25, 0.75), and TE(0.25, 0.75) based on µIPW (z, α) and
µIV (z, α) were computed and corresponding bootstrap confidence intervals (using 200 repli-
cates found by resampling entire groups) were computed for each of 1000 simulated data sets
and were used to estimate the bias, empirical standard error and coverage of the bootstrap
confidence intervals. Estimated bounds based on µLB(z, α) and µUB(z, α) were computed as
well as the length of these bounds. Strong uncertainty regions as found in Vansteelandt et al.
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(2006) were computed by taking the union of bootstrap confidence intervals for the lower and
upper bounds.
As demonstrated by Table 4.1, when all Assumptions 4.1–4.9 are met, estimators based
on µIPW (z, α) and µIV (z, α) are consistent and the coverage of the corresponding confidence
intervals is approximately equal to the nominal 95%. The bounds under this scenario may were
informative (i.e., they exclude 0) for some of the simulated datasets, however inference using
the strong uncertainty regions is quite conservative as evidenced by the estimated coverage
of 100% for each of the causal estimands examined. When Assumptions 4.1–4.4 and 4.7–4.8
are met, but Assumption 4.9 is not met then the estimators based on µIPW (z, α) remain
consistent and the corresponding confidence intervals have approximately 95% coverage as
expected based on the results in Section 4.4. However, estimators based on µIV (z, α) are
not consistent and the corresponding confidence intervals exhibit significant under coverage.
Conversely, when Assumptions 4.1–4.7 and 4.9 are met, but 4.8 is not met then the estimators
based on µIV (z, α) are consistent and the coverage of the corresponding confidence intervals
is approximately nominal as would also be expected given the results in Section 4.4. However,
under this set of assumptions estimators based on µIPW (z, α) are no longer consistent and the
corresponding confidence intervals have lower than nominal coverage (though the coverage is
not as poor as that of the µIV (z, α) estimators when Assumption 4.9 is not met). The bounds
in each of these two scenarios are again conservative with regards to the coverage of the 95%
strong uncertainty regions, but again may be informative. When only Assumptions 4.1–4.4
and 4.7 are met then estimators based on both µIPW (z, α) and µIV (z, α) are not consistent
and the corresponding 95% confidence intervals have poor coverage. However, the bounds still
provide valid (albeit conservative) inference about the interference effects examined. These
bounds were also informative for some of the simulated datasets.
4.7 Motivating Example: Rotavirus Vaccination in U.S. Infants
Panozzo et al. (2014) analyzed data from the MarketScan Research Databases (Thomson
Truven Healthcare, Inc.) that contain information on (i) rotavirus vaccination and (ii) in-
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patient and outpatient claims including diagnoses of acute gastroenteritis (AGE) and more
specifically, rotavirus gastoenteritis (RGE) for privately insured US infants. Infants at least
one outpatient claim and that were born between May 1, 2006 and April 30, 2010 were
extracted from the databases.
To assess the efficacy of rotavirus vaccine (the treatment of interest here) on reducing
rotavirus gastroenteritis (RGE) and/or acute gastroenteritis (AGE) hospitalization, Panozzo
et al. (2014) considered this cohort of infants and compared them to a cohort of infants
born between May 1, 2000 and April 30, 2005 when a rotavirus vaccine was not available.
Indirect effects of rotavirus vaccination were computed by comparing the unvaccinated in
the 2006–2010 cohort to this cohort, and direct effects were computed by comparing the
vaccinated infants in the 2006–2010 cohort to the respective unvaccinated infants in the 2006–
2010 cohorts. Such an analysis provides direct effect estimates for the observed treatment
allocation laws and indirect effects comparing these observed allocation laws to an allocation
law where no one receives treatment. They found that rotavirus vaccination had a direct effect
of reducing rotavirus hospitalization by 87-92% and an indirect effect of reducing rotavirus
vaccination by an additional 3-8%. However, this does not take into account geographic
variation in vaccine coverage.
In order to assess the interference effects in (4.2) and to account for the geographic specific
coverage rates, here we apply above derived results to the data considered by Panozzo et al.
(2014). We consider infants in the 2000–2005 and 2006–2010 cohorts who had at least 9
months of contiguous health insurance enrollment, had data recorded on the county in which
they received health care services, and were enrolled in a county where at least 19 other
infants resided and were included in the database (in order to model the coverage, or Zi,−j
using assuming a continuous distribution). Table 4.2 describes these cohorts of infants in
more detail as well as the groups, which are defined as all captured infants over 6 weeks of
age being provided health care services in the same county. These groups will be used to
define the direct, indirect and total effects of vaccination.
The first dose of rotavirus vaccination should occur by age 4 months and a potential
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instrumental variable might be given by the calendar time in which the infant reaches 4
months of age. Specifically, let Rij = R
p
ijR
z
ij where R
p indicates whether or not the vaccine
was available when the infant reached 4 months of age and Rzij indicates the number of years
since the introduction of the rotavirus vaccine (Feb. 2006) that infant reached 4 months of
age provided Rpi = 1 (rounded to the nearest quarter year). The potential outcomes Zij(rij)
may be interpreted as the vaccination choice of individual j in group i had the vaccine been
available rij years before the infant reached 4 months of age. Figure 4.1 depicts the 3,499
US counties and their estimated rotavirus vaccine coverage in each year from 2006–2010 as
indicated by the Marketscan research databases and demonstrates that calendar time Rzij
appears to have a fairly large positive effect on vaccination choice indicating that calendar
time may be a good instrument for Zij provided that it does not have an effect on the
outcome Yij . Here the outcomes of interest will be an acute gastroenteritis (AGE) diagnosis,
or a rotavirus gastroenteritis (RGE) diagnosis from either an inpatient or an outpatient file
(meaning that diagnoses not resulting in hospitalization were included in this analysis).
The proportion of other group members vaccinated Zi,−j was modeled using a mixed ef-
fects beta regression model with covariates Vi including the rural-urban continuum code of the
county; high, medium or low unemployment in the county (in the year 2006); whether or not
there was a state funded vaccination program and whether or not > 25% of adults completed
a college education. As Zi,−j has repeated measures over calendar time, a random intercept
and calendar time slope for each county was also included. Individual level vaccination Zij |Vi
was modeled using logistic regression with these same covariates and a random intercept for
the county. Table 4.2 gives the observed proportions of each of the levels of the covariates
Vi stratified by year of 4 month birthday Rij for the 936,410 infants in the 2000-2005 and
2006-2010 cohorts.
Estimated values of DE(α), IE(0, α) and TE(0, α) based on (4.3) and 4.6 and estimated
bounds based on (4.4) and (4.5) can be found in Figure 4.2 for various α and for both the AGE
and the RGE outcome. For both the AGE and the RGE outcomes, the estimated indirect
effect based on (4.3) and (4.6) is positive and steadily increases as α increases and the direct
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effect is positive for lower values of α and then turns negative as α increases (at lower values
of α for the AGE outcome than the RGE outcome). The total effect is positive for all α and
slightly increases with α. Bounds for DE(α) based on (4.4) and (4.5) do not include 0 for all
α ≤ 0.33. This indicates that the assumption of no unmeasured confounding for individual
vaccination choice was not necessary in order to determine the sign of the direct effect when
vaccine is coverage is low (for the AGE outcome only). In contrast, bounds for IE(0, α)
based on (4.4) and (4.5) do not include 0 for all α ≥ 0.69, indicating that the assumption
of no unmeasured confounding for individual vaccination choice was not necessary in order
to determine the sign of the indirect effects when there is high coverage (again for the AGE
outcome only). Bounds for TE(0, α) for the AGE outcome exclude 0 for all α.
4.8 Discussion
The results obtained demonstrate that potentially informative bounds for interference
effects may be obtained under a fairly reasonable set of assumptions using an instrumental
variable. The length of the bounds will be related to the ability of the instrumental variable
to predict treatment selection. For rare outcomes, such as the RGE outcome in the rotavirus
example above, bounds based on (4.4) and (4.5) will not be informative unless the instrumental
variable very near perfectly predicts treatment selection. Identification results under two
different sets of assumptions is also given, providing a means for inference about the defined
causal interference effects if the required set of assumptions are considered plausible. All of
these results are corroborated by the simulation study in Section 4.6. Analysis of interference
effects might proceed by comparing the results obtained using the bounds and the estimators
based on µIPW (z, α) and µIV (z, α).
In the rotavirus data, the infants were subject to both administrative censoring and right
censoring due to loss of health insurance enrollment. The results here could easily be extended
to account for right censoring by considering weighted Kaplan Meier estimates of the survival
curve or weighted Cox models or weighted accelerated failure time models. In addition,
bounds without Assumption 4.6 could be found using the simplex algorithm similarly to
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Balke and Pearl (1997).
Assumptions such as 4.7, 4.8 or 4.9 might not be considered valid in general, but mild de-
partures from this assumption could be assessed in a sensitivity analysis. Sensitivity analyses
examining departures from 4.9 may be conducted in a similar fashion to the sensitivity analy-
ses discussed in Robins et al. (1999) in absence of interference. Similarly, mild departures from
Assumptions 4.7 and 4.8 maybe assessed in a sensitivity analysis by positing the existence of
some unmeasured confounding variable Uij as in VanderWeele and Halloran (2014).
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Table 4.1: Simulation study results: true effect (×100), bias (×100), empirical standard error
(ESE, ×100), coverage of confidence intervals and strong uncertainty regions (%) for the
estimators based on µIPW (z, α), µIV (z, α) and the lower (LB) and upper (UB) bounds in 4.4
and 4.5 as well as the length of the bounds.
Coverage
Assumptions Bias ESE CI URs Length
met Effect Truth IPW IV IPW IV IPW IV UB−LB
4.1–4.9 DE(0.25) 23 3.1 -0.2 2.4 2.4 94 97 100 37
IE(0.25, 0.75) 24 2.9 2.3 4.1 4.2 95 96 100 37
TE(0.25, 0.75) 47 3.2 2.6 3.3 3.6 94 97 100 32
4.1–4.8 DE(0.25) 23 3.5 12.2 3.5 6.2 94 34 100 49
IE(0.25, 0.75) 24 2.9 -7.1 3.7 5.1 95 27 100 49
TE(0.25, 0.75) 47 2.7 5.3 3.4 6.4 94 37 100 41
4.1–4.7 & 4.9 DE(0.25) 23 36.1 -0.3 6.5 3.2 79 93 100 50
IE(0.25, 0.75) 24 25.2 0.8 7.0 3.6 24 93 100 53
TE(0.25, 0.75) 47 28.3 0.6 8.4 3.1 78 94 100 42
4.1–4.7 DE(0.25) 24 29.1 -6.3 7.0 2.2 55 54 99 59
IE(0.25, 0.75) 25 7.7 -6.4 7.3 2.9 78 21 99 64
TE(0.25, 0.75) 49 21.4 -9.6 6.9 2.6 57 55 100 49
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Figure 4.1: Map of the US counties estimated rotavirus vaccine coverage by study year
as indicated by color. Deepening shades indicate higher vaccine coverage as indicated by
the legend. Orange or red shaded counties indicate a metropolitan county (100,000 or more
individuals) and blue shaded counties are nonmetropolitan (source: United States Department
of Agriculture, Economic Research Service from the 2010 US census). Grey shaded areas
indicate that no infants were enrolled in the study for that county and study year.
6/2006 6/2007
6/2008 6/2009
6/2010
0-20-40-60-80-100% rotavirus vaccine coverage
metro county
nonmetro county
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Table 4.2: Group level characteristics: rural-urban continuum code of the county; high,
medium or low unemployment in the county (in the year 2006); whether or not there was a
state funded vaccination program and whether or not > 25% of adults completed a college
education (variables Vi) by enrollment year of the infants extracted from the MarketScan
Research Databases and followed for rotavirus or acute gastroenteritis hospitalization (936,410
total infants).
No vaccine, Rpij = 0 Vaccine available, R
p
ij = 1
Years Years, Rzij
2000-01 2002-03 2004-05 2006 2007 2008 2009-10
Rural urban
continuum code
Metro ≥1000k 54.3% 51.3% 58.3% 60.0% 58.9% 61.0% 63.6%
Metro 250k 1000k 21.3% 23.0% 21.6% 20.6% 20.9% 20.4% 20.1%
Metro <250k 9.1% 9.8% 9.0% 9.7% 9.6% 8.8% 8.2%
Urban ≥ 20k:
adjacent to metro 4.7% 4.5% 3.4% 3.6% 3.6% 3.1% 2.9%
not adjacent to metro 1.6% 2.2% 1.6% 1.9% 2.0% 1.8% 1.4%
Urban 2.5–19.999k:
adjacent to metro 4.9% 5.0% 3.6% 2.7% 3.1% 3.0% 2.4%
not adjacent to metro 2.6% 2.8% 1.7% 1.3% 1.6% 1.6% 1.3%
Rural <2.5k:
adjacent to metro 0.6% 0.6% 0.5% 0.1% 0.1% 0.2% 0.1%
not adjacent to metro 0.7% 0.7% 0.4% 0.1% 0.1% 0.1% 0.1%
Unemployment
High (>6.5%) 19.2% 18.9% 26.1% 21.8% 22.2% 20.1% 19.8%
Medium (4-6.5%) 68.9% 67.8% 61.6% 68.5% 67.5% 66.6% 67.4%
Low (< 4%) 11.9% 14.3% 12.2% 9.7% 10.3% 13.2% 12.7%
State vaccination
program N/A N/A N/A 10.0% 8.8% 8.5% 9.5%
> 25% adults
college educated 67.3% 68.7% 69.8% 68.2% 66.8% 69.5% 72.1%
Total 19.9k 123.4k 174.2k 105.7k 145.4k 184.8k 183.1k
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Figure 4.2: Estimates of DE(α), IE(0, α) and TE(0, α) for various α based on µIPW (z, α)
(solid lines), µIV (z, α) (dotted lines) and the bounds based on µLB(z, α) and µUB(z, α)
(shaded area) for the AGE outcome (first row) and the RGE outcome (second row).
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APPENDIX A: TECHNICAL DETAILS FOR CHAPTER 3
A.1 Proof of Proposition 3.1
We seek the asymptotic distribution of
√
n
{
δ̂j(t)− δj(t)
}
=
√
ndp−1
{
d̂F
j
(t)− δj(t)d̂p
}
as n→∞
which is normally distributed with mean 0 because d̂F
j
(t) and d̂p are each asymptotically
normally distributed and the IV estimator is asymptotically consistent for the difference in
the subdistribution curves for the compliers principal strata. Using Slutsky’s theorem, the
variance of δ̂(t) is then given by
var
{
δ̂j(t)
}
= dp−2var
{
d̂F
j
(t)− d̂pδj(t)
}
= dp−2
[
var{d̂F j(t)} − 2δj(t)cov{d̂F j(t), d̂p}+ δj(t)2var(d̂p)
]
.
The influence functions, Li
β̂
for β̂ = d̂F
j
(t) and d̂p are given by
Li
d̂F
j
(t)
=
∑
r
(−1)r
[∫ t
0
Sr(u)
yr(u)
dN jir (u)−
∫ t
0
Y ir (u)Sr(u)
yr(u)
λjr(u)du
−
∫ t
0
Sr(u)λ
j
r(u)
{∫ u
0
1
yr(s)
dN ir(s)−
∫ u
0
Y ir (s)
yr(s)
λr(s)ds
}
du
]
Li
d̂p
=
∑
r
(−1)1−r (I[Zi = 1|Ri = r]− pr)
(Pepe, 1991). Using Le Cam’s third lemma we have the following:
var{d̂F j(t)} = E
[
{Li
d̂F
j
(t)
}2
]
=
∑
r
∫ t
0
Sr(t)
2λ
j
r(u)
yr(u)
du− 2
∫ t
0
Sr(u)
λjr(u)
yr(u)
{∫ t
u
Sr(s)λ
j
r(s)ds
}
du
+
∫ t
0
λr(u)
yr(u)
{∫ t
u
Sr(s)λ
j
r(s)ds
}2
du
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cov{d̂F j(t), d̂p} = E[Li
d̂F
j
(t)
Li
d̂p
]
=
∑
r
[∫ t
0
yr1(u)Sr(u)
yr(u)
{
λjr1(u)− λjr(u)
}
du
−
∫ t
0
Sr(u)λ
j
r(u)
∫ u
0
yr1(s)
yr(s)
{λr1(s)− λr(s)} ds du
]
var(d̂p) = E{(Li
d̂p
)2} =
∑
r
pr(1− pr)
(Pepe, 1991). Results for the asymptotic distribution of
√
n
{
δ̂(t)− δ(t)
}
are obtained using
similar arguments.
A.2 Proof of Proposition 3.2
We seek the asymptotic distribution of
√
n
{
δ̂w(t0)− δw(t0)
}
=
√
ndp−1

t0∫
0
W (u)d̂S(u)du− δw(t0)d̂p
 as n→∞
which is normally distributed with mean 0. Using the continuous mapping theorem
t0∫
0
W (u)d̂S(u)du
is normally distributed. Because d̂p is also normally distributed, Slutsky’s theorem yields that
the variance of δ̂w(t) is given by
var
{
δ̂w(t)
}
= dp−2var

t0∫
0
W (u)d̂S(u)du− d̂pδ(t)

= dp−2
var

t0∫
0
W (u)d̂S(u)du
− 2δw(t0)cov

t0∫
0
W (u)d̂S(u)du, d̂p

+δw(t0)
2var(d̂p)
]
.
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where under the null hypothesis that δw(t0) = 0 the above variance reduces to
var
{
t0∫
0
W (u)d̂S(u)du
}
which is given by
dp−2
 t0∫
0
{∫ t0
t
w(u)S(u)du
}2 {
y0(t)
−1 + y1(t)−1
}
λ(t)dt

(Pepe, 1991). Results for the asymptotic distribution of
√
n
{
δ̂jw(t0)− δjw(t0)
}
are obtained
using similar arguments.
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APPENDIX B: TECHNICAL DETAILS FOR CHAPTER 4
B.1 Proof that 4.3 identifies E[Y ij(z;αp)]
To see that µIPW (z, αp) is equal to E[Y ij(z, αp)] under Assumptions 4.7–4.8 note
E
{
E
[
dFZi,−j |Zij (Zi,−j |Zij ;αp)
dFZi,−j |Vi(Zi,−j |Vi, Rij)dFZij |Vi,Rij (Zij |Vi)
I(Zij = z)Yij(Zij , Zij , Rij)
]}
= E
 1∑
zij=0
∫ 1
0
{
dFZi,−j |Zij (Zi,−j |Zij ;αp)Yij(zij , zi,−j , Rij)I[zij = z]
dFZi,−j |Vi,Rij (Zi,−j |Vi, Rij)dFZij |Vi,Rij (Zij |Vi, Rij)
×
dFZi,−j |Yij(Zij)(zi,−j |Yij(Zij))dFZij |Yij(Zij)(zij |Yij(Zij))
}]
= E
[∫ 1
0
{
dFZi,−j |Zij (Zi,−j |Zij ;αp)
dFZi,−j |Vi,Rij (Zi,−j |Vi)dFZij |Vi,Rij (Zij |Vi, Rij)
Yij(zij , zi,−j , Rij)×
dFZi,−j |Vi,Rij (zi,−j |Vi)dFZij |Vi,Rij (zij |Vi, Rij)
}]
=
∫ 1
0
∫ 1
0
Yij(z, zi,−j , Rij)dFZi,−j |Zij (zi,−j |z;αp)dFY ij(z,αp)(y)
=
∫ 1
0
Y ij(z, αp)dFY ij(z,αp)(y) = E[Y ij(z;αp)].
The first equality comes from Assumption 4.1, the second from Assumptions 4.7–4.8. The
third, fourth and fifth come from properties of expectations and algebraic manipulation.
B.2 Estimation of 4.3
To show that µ̂IPW (z, αp) consistently estimates µ
IPW (z, αp), let
g(Yij , Zij , Zi,−j , z, αp) = dFZi,−j |Zij (zi,−j |z;αp)I[Zij = z]Yij and
ψz,αp(Yij , Zij , Zi,−j , µ(z, αp)) =
g(Yij , Zij , Zi,−j , z, αp)
dFZi,−j |Vi,Rij (Zi,−j |Vi, Rij)dFZij |Vi,Rij (Zij |Vi, Rij)
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then for m =
∑N
i=1 ni
µ̂(z, αp) = m
−1
N∑
i=1
ni∑
j=1
g(Yij , Zij , Zi,−j , z, αp)
dFZi,−j |Vi,Rij (Zi,−j |Vi, Rij)dFZij |Vi,Rij (Zij |Vi, Rij)
and µ̂(z, αp) is a solution (for µ(z, αp)) to the estimating equation
N∑
i=1
ni∑
j=1
ψz,αp(Yij , Zij , Zi,−j , µ(z, αp)) = 0.
Thus, by M-estimation theory µ̂(z, αp)
p→ µ(z, αp) provided
d̂FZi,−j |Vi,Rij (Zi,−j |Vi, Rij)d̂FZij |Vi,Rij (Zij |Vi, Rij)
p→
dFZi,−j |Vi,Rij (Zi,−j |Vi, Rij)dFZij |Vi,Rij (Zij |Vi, Rij)
.
B.3 Proof that 4.4 and 4.5 are sharp bounds
To see that the bounds in (4.4) and (4.5) are sharp, let L′ij = {Y ij(z, αp, r), Zij(r) :
r ∈ R, Vi, Rij}, L the set of all possible realizations of Lij and
pzr(αp) =
∫
l∈Pzr
Y ij(z, αp, r)dFLij (l)
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where Pzr is the set of all realizations of Lij such that Zij(r) = z. Note that
E
{
E
[
dFZi,−j (Zi,−j |Zij ;αp)
dFZi,−j |Vi,Rij (Zi,−j |Vi, Rij)
I(Zij(Rij) = z)Yij(Zij(Rij), Zi,−j , Rij)|Rij = r
]}
= E
[∫ 1
0
{
dFZi,−j |Zij (zi,−j |zij ;αp)
dFZi,−j |Vi,r(zi,−j |Vi, r)
Yij(Zij(r), zi,−j)I[Zij(r) = z]×
dFZi,−j |Yij(Zij)(zi,−j |Yij(Zij))
}]
= E
[∫ 1
0
{
dFZi,−j |Zij (zi,−j |zij ;αp)
dFZi,−j |Vi,Rij (zi,−j |Vi, r)
Yij(z, zi,−j , r)dFZi,−j |Vi,Rij (zi,−j |Vi, r)
}]
=
∫
l∈Pzrv
∫ 1
0
Yij(z, zi,−j , r)dFZi,−j |Zij (zi,−j |zij ;αp)dFLij (l)
=
∫
l∈Pzr
Y ij(z, αp, r)dFLij (l) = pzr(αp)
(B.3.1)
for all r ∈ R and Vi ∈ V. The first line again comes from Assumption 4.1. The first equality
(2nd line) comes from Assumption 4.5. The second equality (3rd line) comes from Assumption
4.7. Note also that
E[Y ij(z, α)] =
∫
l∈L
Y ij(z, αp, r)dFLij (l)
=
∫
l∈Pzr
Y ij(z, αp, r)dFLij (l) +
∫
l∈{L−Pzr}
Y ij(z, αp, r)dFLij (l)
= pzr(αp;Vi) +
∫
l∈{L−Pzt}
Y ij(z, αp, r)dFLij (l)
for all r ∈ R under Assumption 4.4. Because pzr(αp) is identified from the observable data,
bounds for E[Y ij(z, α)] may be found by maximizing and minimizing
qzr(αp) =
∫
l∈{L−Pzr}
Y ij(z, αp, r)dFLij (l).
A lower bound in qzr is reached when Y (z, αp, r) = 0 for all Lij ∈ L − Pzr and an upper
bound when Y (z, αp, r) = 1. Thus a lower bound is given by maxr∈R pzr (by Assumption
4.4) and an upper bound is given by minr∈R{pzr + Pr[l ∈ {L−Pzr}]. Under Assumption 4.6,
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Pr[Lij ∈ {L − Pzr}] = Pr[Zij(r) = 1 − z] = Pr[Zij = 1 − z]. These results will hold within
strata defined by Vi = v and thus a tight lower and upper bound maybe computed by finding
bounds within these strata and then integrating across Vi as in the bounds in (4.4)–(4.5).
B.4 Proof that 4.6 identifies 4.2
To see that DE(α0) is given by the expression in (4.6) under Assumptions 4.3–4.7 and 4.9
note that the numerator of the estimand for DE(α0)
E[Y wij (α0;Vi, Rij)|Rij = rl]− E[α0;ViRij |Rij = ru]
=
1∑
z=0
E[Y wij (α0;Vi, Rij)I[Z(rl) = z]|Rij = rl]− E[Y wij (α0;Vi, Rij)I[Zij(ru) = z]|Rij = ru]
=E[(Y ij(0, α0)− Y ij(1, α0;Vi, Rij))(Zij(ru)− Zij(rl))]
=E[Y ij(0, α0)− Y ij(1, α0;Vi, Rij)|Zij(ru) > Zij(rl)] Pr[Zij(ru) > Zij(rl)]
=E[Y ij(0, α0)− Y ij(1, α0;Vi, Rij)|Zij(ru) > Zij(rl)](drE[Zij ]). (B.4.1)
The first equality comes from properties of expectations, the second from rearranging terms
and applying the results in (B.3.1). The third and fourth equalities come from Assumption
4.6. Continuing,
E[Y ij(0, α0)− Y ij(1, α0;Vi, Rij)|Zij(ru) > Zij(rl)]
=E[Y ij(0, α0)− Y ij(1, α0;Vi, Rij)|Zij(ru) = 1, Zij(rl) = 0]
=E[Y ij(0, α0)− Y ij(1, α0;Vi, Rij)|Zij = 1, Rij = ru] or
E[Y ij(0, α0)− Y ij(1, α0;Vi, Rij)|Zij = 0, Rij = rl].
E[Y ij(0, α0)− Y ij(1, α0;Vi, Rij)|Zij = 1, Rij = ru]
=E[Y ij(0, α0)− Y ij(1, α0;Vi, Rij)|Zij = 1, Rij = r] and
E[Y ij(0, α0)− Y ij(1, α0;Vi, Rij)|Zij = 0, Rij = rl]
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=E[Y ij(0, α0)− Y ij(1, α0;Vi, Rij)|Zij = 0, Rij = r]
for all r ∈ R.
The first equality holds because Zij is dichotomous and the second and third equalities come
from Assumption 4.1. The fourth and fifth equalities hold due to Assumption 4.9. The above
equalities yield that E[Y ij(0, α0) − Y ij(1, α0)] = E[Y ij(0, α0) − Y ij(1, α0;Vi, Rij)|Zij(ru) >
Zij(rl)] and thus that DE(α0) is identified and given by the expression in (4.6).
To see that IE(α0, α1) is identified and equal to the estimand in (4.6) note that
E[Y wij (α0;Vi, Rij)− Y wij (α1;Vi, Rij)|Rij = rl]
=
1∑
z=0
E[(Y wij (α0;Vi, Rij)− Y wij (α1;Vi, Rij))I[Z(rl) = z]|Rij = rl]
={E[Y ij(1, α0)− Y ij(0, α0)|Z = 1, R = rl]
− E[Y ij(1, α1)− Y ij(0, α1)|Z = 1, R = rl]}E[Zij |Rij = rl] + IE(α0, α1). (B.4.2)
And similarly,
E[Y wij (α0;Vi, Rij)− Y wij (α1;Vi, Rij)|Rij = ru]
=
1∑
z=0
E[(Y wij (α0;Vi, Rij)− Y wij (α1;Vi, Rij))I[Z(rl) = z]|Rij = ru]
={E[Y ij(1, α0)− Y ij(0, α0)|Z = 1, R = ru]
− E[Y ij(1, α1)− Y ij(0, α1)|Z = 1, R = ru]}E[Zij |Rij = ru] + IE(α0, α1)
={E[Y ij(1, α0)− Y ij(0, α0)|Z = 1, R = rl]
− E[Y ij(1, α1)− Y ij(0, α1)|Z = 1, R = rl]}E[Zij |Rij = ru] + IE(α0, α1). (B.4.3)
Solving (B.4.2) for {E[Y ij(1, α0)− Y ij(0, α0)|Z = 1, R = rl] − E[Y ij(1, α1)− Y ij(0, α1)|Z =
1, R = rl]}E[Zij |Rij = ru] and plugging this into (B.4.3) and solving for IE(α0, α1) yields the
estimand in (4.6) which is composed of identifiable quantities.
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